{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "cd587aa8",
   "metadata": {},
   "source": [
    "**Wesite link**\n",
    "\n",
    "https://www.novonordisk.com/news-and-media/news-and-ir-materials.html\n",
    "\n",
    "**API**\n",
    "\n",
    "https://www.novonordisk.com/bin/nncorp/news-search?searchtext=null&start=2000-01-01&end=2022-05-24&newspath=/content/dam/nncorp/global/en/investors/content-fragments/ir-materials&limit=10&currentresults=10&function=search&language=all&type=Annual%20reports,Investor%20presentations,5355,5356"
   ]
  },
  {
   "cell_type": "raw",
   "id": "d95da545",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T09:06:10.315631Z",
     "start_time": "2022-05-24T09:06:10.297680Z"
    }
   },
   "source": [
    "https://www.novonordisk.com/bin/nncorp/news-search?searchtext=null&start=2000-01-01&end=2022-05-24&newspath=/content/dam/nncorp/global/en/investors/content-fragments/ir-materials&limit=10&currentresults=0&function=search&language=all&type=Annual%20reports,Investor%20presentations,5355,5356"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "210a803a",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:01.344125Z",
     "start_time": "2022-05-24T13:46:00.610159Z"
    }
   },
   "outputs": [
    {
     "data": {
      "application/javascript": [
       "IPython.notebook.set_autosave_interval(1000)"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Autosaving every 1 seconds\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd,requests,bs4,time\n",
    "from datetime import datetime\n",
    "from bs4 import BeautifulSoup\n",
    "import warnings\n",
    "warnings.filterwarnings(\"ignore\")\n",
    "\n",
    "%autosave 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "04db1c2e",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:01.360046Z",
     "start_time": "2022-05-24T13:46:01.346085Z"
    }
   },
   "outputs": [],
   "source": [
    "def parse_webpage_api(url):\n",
    "    try:\n",
    "        headers = {\n",
    "            \"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64; rv:90.0) Gecko/20100101 Firefox/90.0\"}\n",
    "        api_request = requests.get(url, headers=headers, timeout=20)\n",
    "        if api_request.status_code==200:\n",
    "            data = api_request.json()\n",
    "            return data\n",
    "        else:\n",
    "            print(\"Access Denied\")\n",
    "    except:\n",
    "        return []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "d9bd2123",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:01.375007Z",
     "start_time": "2022-05-24T13:46:01.363043Z"
    }
   },
   "outputs": [],
   "source": [
    "def remove_esc_chars(text):\n",
    "    return text.replace(\"\\n\", \" \").replace(\"\\t\", \" \").replace(\"\\r\", \" \")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "813c2899",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:01.390443Z",
     "start_time": "2022-05-24T13:46:01.376005Z"
    }
   },
   "outputs": [],
   "source": [
    "SITE_NAME='Novonordisk'\n",
    "\n",
    "DOMAIN = \"https://www.novonordisk.com\"\n",
    "\n",
    "SITE_LINK=\"https://www.novonordisk.com/news-and-media/news-and-ir-materials.html\""
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ba7cd9a",
   "metadata": {},
   "source": [
    "for pagination we can change the limit value  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "3b278221",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:07.434586Z",
     "start_time": "2022-05-24T13:46:01.391441Z"
    },
    "code_folding": [],
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2022-05-10 Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines\n",
      "2022-05-06 Novo Nordisk A/S:\n",
      "2022-05-02 Novo Nordisk – major shareholder announcement\n",
      "2022-04-29 Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2022\n",
      "2022-04-29 Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022\n",
      "2022-04-29 Novo Nordisk's sales increased by 24% in Danish kroner and by 18% at constant exchange rates to DKK 42.0 billion in the first three months of 2022\n",
      "2022-04-28 Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial\n",
      "2022-04-27 Novo Nordisk A/S – Reduction of the share capital\n",
      "2022-03-28 Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes\n",
      "2022-03-24 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2022-03-14 Novo Nordisk – major shareholder announcement\n",
      "2022-03-09 Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines\n",
      "2022-03-04 Novo Nordisk – major shareholder announcement\n",
      "2022-03-03 Highlights to be presented at Novo Nordisk’s Capital Markets Day 2022\n",
      "2022-02-28 Election of employee representatives to the Board of Directors of Novo Nordisk A/S\n",
      "2022-02-21 Novo Nordisk – major shareholder announcement\n",
      "2022-02-21 Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2022-02-14 Novo Nordisk – major shareholder announcement\n",
      "2022-02-02 Novo Nordisk files annual report with the SEC\n",
      "2022-02-02 Novo Nordisk's sales increased by 11% in Danish kroner and by 14% at constant exchange rates to DKK 140.8 billion in 2021\n",
      "2022-01-14 Novo Nordisk announces settlement of securities lawsuit in Denmark\n",
      "2021-12-28 Novo Nordisk announces completion of Dicerna Pharmaceuticals acquisition\n",
      "2021-12-17 Novo Nordisk announces supply challenges for Wegovy® in the US\n",
      "2021-12-13 Novo Nordisk invests more than DKK 17 bn in expansion of the manufacturing facilities in Kalundborg, Denmark\n",
      "2021-12-13 Novo Nordisk investerer mere end 17 mia. kr. i udbygning af produktionsfaciliteterne i Kalundborg\n",
      "2021-11-26 Novo Nordisk announces impact from Volume Based Procurement for insulin in China\n",
      "2021-11-18 Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform\n",
      "2021-11-12 Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency\n",
      "2021-11-11 Wegovy™ recommended for approval for the treatment of obesity by the European regulatory authorities\n",
      "2021-11-03 Novo Nordisk's net profit increased by 12% in the first nine months of 2021\n",
      "2021-10-29 Novo Nordisk raises sales and operating profit outlook for 2021\n",
      "2021-09-24 Novo Nordisk announces settlement of US securities class action litigation\n",
      "2021-08-04 Novo Nordisk's net profit increased by 10% in the first six months of 2021\n",
      "2021-08-04 Novo Nordisk's net profit increased by 10% in the first six months of 2021\n",
      "2021-07-12 Prothena and Novo Nordisk announce acquisition agreement for Prothena’s ATTR amyloidosis programme\n",
      "2021-06-04 Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US\n",
      "2021-06-01 Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure\n",
      "2021-05-28 Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval\n",
      "2021-05-27 Novo Nordisk successfully prices EUR 1.3 billion notes under its newly established Euro Medium Term Note programme\n",
      "2021-05-21 Novo Nordisk establishes Euro Medium Term Note programme\n",
      "2021-05-07 Novo Nordisk A/S – Share repurchase programme\n",
      "2021-05-07 Novo Nordisk A/S purchases B shares worth DKK 2,586 million from Novo Holdings A/S under the 2021 share repurchase programme\n",
      "2021-05-05 Novo Nordisk's net profit increased by 6% in the first three months of 2021\n",
      "2021-04-29 Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2021\n",
      "2021-04-27 Novo Nordisk A/S – Reduction of the share capital\n",
      "2021-04-21 Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide\n",
      "2021-03-25 Correction: Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2021-03-25 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2021-03-22 Novo Nordisk receives Refusal to File letter for once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes\n",
      "2021-03-18 Gilead Sciences and Novo Nordisk expand NASH clinical collaboration\n",
      "2021-02-24 Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention\n",
      "2021-02-23 Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2021-02-11 Novo Nordisk files annual report with the SEC\n",
      "2021-02-04 Novo Nordisk files annual report with the SEC\n",
      "2021-02-03 Novo Nordisk's net profit increased by 8% in 2020\n",
      "2021-01-20 Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes\n",
      "2020-12-29 Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes\n",
      "2020-12-18 Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.4 mg for weight management\n",
      "2020-12-16 Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide\n",
      "2020-12-08 Novo Nordisk announces completion of the Emisphere Technologies acquisition\n",
      "2020-12-04 Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management\n",
      "2020-11-17 Once-weekly semaglutide 2.0 mg demonstrates superior reduction in HbA1c vs once-weekly semaglutide 1.0 mg in people with type 2 diabetes in the SUSTAIN FORTE trial\n",
      "2020-11-15 Gilead and Novo Nordisk present new data from proof-of-concept trial in NASH\n",
      "2020-11-06 Novo Nordisk to acquire Emisphere Technologies and obtain ownership of the Eligen® SNAC oral delivery technology\n",
      "2020-10-30 Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020\n",
      "2020-10-08 Novo Nordisk raises sales and operating profit outlook for 2020\n",
      "2020-09-21 Novo Nordisk lancerer nyt mål om 100% grøn strøm for leverandører\n",
      "2020-09-21 Novo Nordisk launches new 100% renewable power target for suppliers\n",
      "2020-08-14 Novo Nordisk investerer 850 millioner kroner i produktionsfaciliteterne i Kalundborg\n",
      "2020-08-14 Novo Nordisk invests DKK 850 million in production facilities in Kalundborg\n",
      "2020-08-06 Novo Nordisk's operating profit increased by 9% in Danish kroner and by 8% at constant exchange rates (CER) in the first six months of 2020\n",
      "2020-06-29 Rybelsus® approved in Japan for the treatment of type 2 diabetes\n",
      "2020-06-18 Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity\n",
      "2020-06-12 Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme\n",
      "2020-06-11 Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascular disease\n",
      "2020-06-04 Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial\n",
      "2020-06-02 EU-supported international research project aims to improve obesity treatment and change the narrative around obesity\n",
      "2020-05-27 Novo Nordisk launches new social responsibility strategy to defeat diabetes\n",
      "2020-05-27 Novo Nordisk lancerer ny strategi for social ansvarlighed\n",
      "2020-05-13 Semaglutide 2.4 mg demonstrates superior and sustained weight loss versus placebo and in addition a 17.4% weight loss after 68 weeks in STEP 4 trial\n",
      "2020-05-06 Novo Nordisk's sales increased by 16% in Danish kroner and by 14% at constant exchange rates (CER) to DKK 33.9 billion in the first three months of 2020\n",
      "2020-04-30 Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2020\n",
      "2020-04-28 Novo Nordisk A/S – Reduction of the share capital\n",
      "2020-04-04 Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU\n",
      "2020-03-26 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2020-03-16 Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) in haemophilia A and B with or without inhibitors\n",
      "2020-02-21 Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2020-02-07 Novo Nordisk invests DKK 800 million in upgrading and expanding production facilities in Kalundborg\n",
      "2020-02-05 Novo Nordisk files annual report with the SEC\n",
      "2020-02-05 Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at constant exchange rates (CER) in 2019\n",
      "2020-01-31 Rybelsus® (oral semaglutide) recommended for approval for the treatment of adults with type 2 diabetes by the European regulatory authorities\n",
      "2020-01-16 Ozempic® approved in the US for CV risk reduction in people with type 2 diabetes and established CVD\n",
      "2019-12-30 Financial calendar 2020\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2019-12-19 University of Virginia Center for Diabetes Technology and Novo Nordisk enter into research collaboration to develop virtual patient modelling for type 2 diabetes\n",
      "2019-11-20 Novo Nordisk and UNICEF announce new partnership  to help prevent childhood overweight and obesity\n",
      "2019-11-20 Novo Nordisk expects to meet its current long-term financial targets and introduces strategic aspirations at the Capital Markets Day 2019\n",
      "2019-11-18 Dicerna and Novo Nordisk enter agreement to discover and develop RNAi therapies for liver-related cardio-metabolic diseases\n",
      "2019-11-07 Novo Nordisk obtains exclusive worldwide licence to potential NASH candidate UD-014 from UBE Industries\n",
      "2019-11-01 Novo Nordisk's operating profit increased by 11% in Danish kroner and by 5% at constant exchange rates (CER) in the first nine months of 2019\n",
      "2019-10-09 bluebird bio and Novo Nordisk enter into research agreement to develop in vivo genome editing candidates for haemophilia and other severe genetic diseases\n",
      "2019-10-01 Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off\n",
      "2019-09-20 Rybelsus® (semaglutide tablets), the first GLP-1 in a tablet approved in the US\n",
      "2019-09-16 Medtronic and Novo Nordisk enter agreement to provide integrated digital solutions for people with diabetes\n",
      "2019-08-16 Novo Nordisk A/S: Securities lawsuit filed in Denmark against Novo Nordisk\n",
      "2019-08-09 Novo Nordisk's operating profit increased by 12% in Danish kroner and by 6% at constant exchange rates (CER) in the first six months of 2019\n",
      "2019-06-20 Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU\n",
      "2019-05-03 Novo Nordisk's operating profit increased by 14% in Danish kroner and by 8% at constant exchange rates (CER) in the first three months of 2019\n",
      "2019-04-30 Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2019\n",
      "2019-04-30 Novo Nordisk to achieve target of 100% renewable power in production and launches new ambition aiming for zero environmental impact\n",
      "2019-04-30 Novo Nordisk når mål om 100% grøn strøm i produktionen i 2020 og lancerer ny ambition, der sigter mod nul miljøpåvirkning\n",
      "2019-04-26 Novo Nordisk receives positive opinion from the European regulatory authorities for Esperoct® (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A\n",
      "2019-04-26 Novo Nordisk files for EU regulatory approval of oral semaglutide for the treatment of type 2 diabetes\n",
      "2019-04-24 Novo Nordisk A/S - Reduction of the share capital\n",
      "2019-04-12 Gilead Sciences and Novo Nordisk announce intent to initiate a clinical collaboration in NASH\n",
      "2019-03-29 Novo Nordisk investerer 650 mio. kr. i optimering og udvidelse af produktionsfaciliteterne i Kalundborg\n",
      "2019-03-29 Novo Nordisk invests DKK 650 million in upgrading and expanding production facilities in Kalundborg\n",
      "2019-03-21 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2019-03-20 Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic®\n",
      "2019-03-18 Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva\n",
      "2019-02-22 Novo Nordisk: Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2019-02-20 Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin\n",
      "2019-02-19 Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)\n",
      "2019-02-05 Novo Nordisk files annual report with the SEC\n",
      "2019-02-01 Novo Nordisks resultat af primær drift faldt med 4% opgjort i kroner og steg med 3% i lokale valutaer i 2018\n",
      "2019-02-01 Novo Nordisk's operating profit decreased by 4% in Danish kroner and increased by 3% in local currencies in 2018\n",
      "2018-12-17 Staten Biotechnology B.V. and Novo Nordisk A/S announce collaboration to develop novel treatment for dyslipidaemia\n",
      "2018-11-23 Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial\n",
      "2018-11-23 Oral semaglutid viser en positiv kardiovaskulær sikkerhedsprofil og en signifikant reduktion i hjerte-kar-dødsfald og den samlede dødelighed hos mennesker med type 2-diabetes i PIONEER 6-studiet\n",
      "2018-11-22 Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza® in Japanese people with type 2 diabetes\n",
      "2018-11-22 Oral semaglutid giver større reduktioner i både langtidsblodsukker og vægt sammenlignet med Victoza® hos japanere med type 2-diabetes\n",
      "2018-11-02 Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease\n",
      "2018-11-01 Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018\n",
      "2018-11-01 Novo Nordisks resultat af primær drift faldt med 6% opgjort i kroner og steg med 2% i lokale valutaer i de første ni måneder af 2018\n",
      "2018-10-31 Novo Nordisk expands its biopharm business with the acquisition of the US and Canadian rights to Macrilen(TM)\n",
      "2018-10-31 Novo Nordisk udvider sin biopharm-forretning med køb af de amerikanske og canadiske rettigheder til Macrilen(TM)\n",
      "2018-10-26 Oral semaglutid giver statistisk signifikante reduktioner i langtidsblodsukker og vægt hos mennesker, som længe har haft type 2-diabetes og får insulinbehandling\n",
      "2018-10-26 Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin\n",
      "2018-10-15 Novo Nordisk udnævner Ludovic Helfgott til koncerndirektør for Biopharm\n",
      "2018-10-15 Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm\n",
      "2018-10-12 Fiasp® is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart\n",
      "2018-10-02 Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention\n",
      "2018-10-02 People with diabetes may achieve improved glycaemic control with Tresiba® versus glargine U100, without an increase in hypoglycaemia\n",
      "2018-10-02 Ryzodeg® offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart\n",
      "2018-10-01 Novo Nordisk to establish California manufacturing site for stem cell-based therapies\n",
      "2018-10-01 Novo Nordisk etablerer produktionsanlæg i Californien til fremstilling af stamcellebaseret behandling\n",
      "2018-10-01 Novo Nordisk plans first global launch of connected insulin pens and announces key digital health partnerships\n",
      "2018-10-01 Novo Nordisk planlægger første globale lancering af intelligente insulinpenne og annoncerer vigtige partnerskaber indenfor digital sundhed\n",
      "2018-09-28 International Diabetes Federation (IDF) global survey reveals 2 in 3 people with type 2 diabetes have cardiovascular disease risk factors and/or have experienced a cardiovascular event\n",
      "2018-09-28 Global undersøgelse viser, at 2 ud af 3 med type 2-diabetes har risikofaktorer for hjerte-kar-sygdom og/eller har haft et hjerte-kar-tilfælde\n",
      "2018-09-28 New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency\n",
      "2018-09-24 Danish Government and Novo Nordisk first to partner with UN-anchored initiative on non-communicable diseases\n",
      "2018-09-24 Den danske regering og Novo Nordisk indgår partnerskab med FN-forankret initiativ til bekæmpelse af ikke-smitsomme sygdomme\n",
      "2018-09-20 Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes\n",
      "2018-09-20 Novo Nordisk - Oral semaglutid viser større reduktioner i langtidsblodsukker og vægt og et sammenligneligt antal bivirkninger sammenlignet med dulaglutid hos japanere med type 2-diabetes\n",
      "2018-09-18 Novo Nordisk announces plans to transform its approach to Research & Development\n",
      "2018-09-18 Novo Nordisk annoncerer planer om markante ændringer i tilgangen til forskning og udvikling\n",
      "2018-08-26 Ozempic® consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline\n",
      "2018-08-26 Ozempic® reducerer risikoen for alvorlig kardiovaskulær sygelighed hos type 2 diabetikere med høj risiko for hjerte-kar-sygdom uanset forekomsten af tidligere kardiovaskulær hændelse\n",
      "2018-08-20 Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial\n",
      "2018-08-20 Oral semaglutid giver større reduktioner i langtidsblodsukker og vægt sammenlignet med placebo hos mennesker med type 2-diabetes og nedsat nyrefunktion i PIONEER 5-studiet\n",
      "2018-08-17 Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins\n",
      "2018-08-17 Novo Nordisk køber Ziylo Ltd med det formål at fremskynde udviklingen af glukoseresponsive insuliner\n",
      "2018-08-08 Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 4% in local currencies in the first six months of 2018\n",
      "2018-08-08 Novo Nordisks resultat af primær drift faldt med 8% opgjort i kroner og steg med 4% i lokale valutaer i de første seks måneder af 2018\n",
      "2018-06-28 Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3\n",
      "2018-06-28 Oral semaglutid viser større reduktioner i langtidsblodsukker og vægt end sitagliptin i langtidsstudie af sikkerhed og effekt (PIONEER 3)\n",
      "2018-06-23 Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial\n",
      "2018-06-23 Oral semaglutid sænker blodsukkeret signifikant sammenlignet med placebo i PIONEER 1-studiet\n",
      "2018-06-23 Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis\n",
      "2018-06-23 Ozempic® giver større vægttab hos voksne med type 2-diabetes og et BMI på 25 eller derover end dem med BMI under 25, viser en SUSTAIN 7 post hoc-analyse\n",
      "2018-06-23 Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study\n",
      "2018-06-23 Real-world-studie viser, at Tresiba® medfører signifikant forbedret blodsukkerregulering og lavere forekomst af hypoglykæmi sammenlignet med insulin glargin U300\n",
      "2018-06-23 Significant blood sugar improvement with Xultophy® compared to insulin glargine U-100 when used as add-on to oral diabetes medications\n",
      "2018-06-23 Xultophy® medfører signifikant forbedring af blodsukker sammenlignet med insulin glargin U-100 givet som supplement til diabeteslægemidler i tabletform\n",
      "2018-06-20 Oral semaglutide shows statistically significantly greater reductions in HbA1c and weight compared to Victoza® and sitagliptin in the PIONEER 4 and 7 trials\n",
      "2018-06-20 Oral semaglutid viser statistisk signifikant større reduktioner i langtidsblodsukker og vægt sammenlignet med Victoza® og sitagliptin i PIONEER 4 og 7\n",
      "2018-06-19 Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes\n",
      "2018-06-19 Kallyope og Novo Nordisk indleder samarbejde om opdagelse af nye lægemidler til behandling af svær overvægt og diabetes\n",
      "2018-05-29 Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial\n",
      "2018-05-29 Oral semaglutid viser større forbedring i langtidsblodsukker sammenlignet med empagliflozin i PIONEER 2-studiet\n",
      "2018-05-24 Real-world evidence shows clinically meaningful weight loss in people receiving Saxenda®\n",
      "2018-05-24 Nyt real-world-studie viser, at behandling med Saxenda® medfører klinisk betydningsfuldt vægttab\n",
      "2018-05-21 NovoEight® maintains potency when stored at 40ºC offering people with haemophilia A increased flexibility in their daily lives\n",
      "2018-05-21 NovoEight® fastholder sin styrke ved opbevaring ved 40 ºC og giver dermed mennesker med hæmofili A større fleksibilitet i hverdagen\n",
      "2018-05-16 Novo Nordisk increases commitment to stem cell-based therapies\n",
      "2018-05-16 Novo Nordisk øger fokus på stamcellebaseret behandling\n",
      "2018-05-02 Novo Nordisk's operating profit decreased by 8% in Danish kroner and increased by 6% in local currencies in the first three months of 2018\n",
      "2018-05-02 Novo Nordisks resultat af primær drift faldt med 8% opgjort i kroner og steg med 6% i lokale valutaer i de første tre måneder af 2018\n",
      "2018-05-01 Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes\n",
      "2018-05-01 Novo Nordisk deltager i Hypo-RESOLVE - et nyt forskningsprojekt om hypoglykæmi og diabetes\n",
      "2018-04-30 Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2018\n",
      "2018-04-30 Novo Nordisk A/S - Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2018\n",
      "2018-04-24 Novo Nordisk A/S - Reduction of the share capital\n",
      "2018-04-24 Novo Nordisk A/S - Nedsættelse af aktiekapitalen\n",
      "2018-04-18 Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises\n",
      "2018-04-18 Røde Kors og Novo Nordisk indgår nyskabende samarbejde om behandling af kroniske sygdomme under humanitære kriser\n",
      "2018-04-05 Novo Nordisk obtains exclusive worldwide licence to EpiDestiny's sickle cell disease programme\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2018-04-05 Novo Nordisk køber eksklusive globale rettigheder til EpiDestinys udviklingsprogram indenfor seglcelleanæmi\n",
      "2018-03-26 FDA approves inclusion of data on cardiovascular outcomes and severe hypoglycaemia in the Tresiba® label\n",
      "2018-03-26 FDA godkender opdatering af indlægssedlen for Tresiba® med data for forekomsten af hjerte-kar-sygdom og alvorlig hypoglykæmi\n",
      "2018-03-23 Ozempic® approved in Japan for the treatment of type 2 diabetes\n",
      "2018-03-23 Ozempic® godkendt i Japan til behandling af type 2-diabetes\n",
      "2018-03-22 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2018-03-22 Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S\n",
      "2018-02-27 Novo Nordisk files for regulatory approval of long-acting factor VIII (N8-GP) in the US and the EU for treatment of haemophilia A\n",
      "2018-02-27 Novo Nordisk indsender registreringsansøgning for langtidsvirkende faktor VIII (N8-GP) i USA og EU til behandling af hæmofili A\n",
      "2018-02-26 Novo Nordisk A/S: Election of employee representatives to the Board of Directors of Novo Nordisk A/\n",
      "2018-02-26 Novo Nordisk A/S: Valg af medarbejderrepræsentanter til bestyrelsen i Novo Nordisk A/S\n",
      "2018-02-23 Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2018-02-23 Indkaldelse til ordinær generalforsamling i Novo Nordisk A/S\n",
      "2018-02-22 Novo Nordisk successfully completes the first phase 3a trial, PIONEER 1, with oral semaglutide\n",
      "2018-02-22 Novo Nordisk: Første fase 3a-studie med oral semaglutid, PIONEER 1, afsluttet med succes\n",
      "2018-02-09 Novo Nordisk A/S: Ozempic® (semaglutide) approved in the EU for the treatment of type 2 diabetes\n",
      "2018-02-09 Novo Nordisk A/S: Ozempic® (semaglutid) godkendt i EU til behandling af type 2-diabetes\n",
      "2018-02-08 Novo Nordisk files annual report with the SEC\n",
      "2018-02-06 Novo Nordisk publishes its 2017 Annual Report\n",
      "2018-02-06 Novo Nordisk har udgivet sin årsrapport for 2017\n",
      "2018-02-01 Novo Nordisk increased reported operating profit by 1% in 2017 to DKK 49 billion (5% growth in local currencies)\n",
      "2018-02-01 Novo Nordisks rapporterede resultat af primær drift steg med 1% i 2017 til 49 mia. kr. (5% vækst i lokale valutaer)\n",
      "2018-01-29 Novo Nordisk does not intend to make a revised proposal for Ablynx\n",
      "2018-01-29 Novo Nordisk vil ikke fremsætte revideret forslag om overtagelse af Ablynx\n",
      "2018-01-08 Novo Nordisk has proposed to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights\n",
      "2018-01-08 Novo Nordisk har foreslået at erhverve Ablynx for op til 30,50 EUR pr. aktie i kontant vederlag, heraf 28,00 EUR ved overtagelsen og €2,50 i betingede vederlagsrettigheder (Contingent Value Rights)\n",
      "2017-12-15 Ozempic® (semaglutide) recommended for approval by the European regulatory authorities\n",
      "2017-12-15 Ozempic® (semaglutid) får anbefaling om godkendelse fra de europæiske lægemiddelmyndigheder\n",
      "2017-12-07 Tresiba® reduces hypoglycaemia regardless of blood sugar level\n",
      "2017-12-07 Tresiba® giver færre tilfælde af hypoglykæmi uanset blodsukkerniveau\n",
      "2017-12-07 Ryzodeg® significantly reduces the risk of low blood sugar in people with type 2 diabetes who fast during Ramadan\n",
      "2017-12-07 Ryzodeg® reducerer risikoen for lavt blodsukker hos mennesker med type 2-diabetes, som faster under ramadanen\n",
      "2017-12-06 Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk\n",
      "2017-12-06 Foreløbige resultater fra global undersøgelse viser, at mennesker med type 2-diabetes undervurderer deres risiko for hjerte-kar-sygdom\n",
      "2017-12-05 Ozempic® (semaglutide) approved in the US\n",
      "2017-12-05 Ozempic® (semaglutid) godkendt i USA\n",
      "2017-12-05 Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial\n",
      "2017-12-05 Xultophy® vurderes som en bedre behandlingsmulighed end basal-bolus-insulinbehandling af deltagere med type 2-diabetes i DUAL VII-studiet\n",
      "2017-11-21 Highlights to be presented at Novo Nordisk's Capital Markets Day 2017\n",
      "2017-11-21 Novo Nordisks kapitalmarkedsdag 2017\n",
      "2017-11-01 Novo Nordisks rapporterede resultat af primær drift steg med 5% i de første ni måneder af 2017\n",
      "2017-11-01 Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017\n",
      "2017-10-31 New US study reveals key reasons why millions of people with obesity are not receiving adequate care\n",
      "2017-10-31 Nyt amerikansk studie afdækker årsager til, at millioner af svært overvægtige ikke får tilstrækkelig behandling\n",
      "2017-10-26 Global city leaders: cut obesity by a quarter to prevent 100m new diabetes cases by 2045\n",
      "2017-10-26 Globale storbyer: svær overvægt skal reduceres med en fjerdedel for at forhindre 100 mio. nye tilfælde af diabetes frem mod 2045\n",
      "2017-10-18 FDA's rådgivende komite stemmer 16-0 til fordel for godkendelse af semaglutid\n",
      "2017-10-18 Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee\n",
      "2017-10-16 Novo Nordisk: FDA offentliggør briefingmateriale forud for møde i rådgivende komite om semaglutid\n",
      "2017-10-16 Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting for semaglutide\n",
      "2017-09-29 Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US\n",
      "2017-09-29 Novo Nordisks nye hurtigtvirkende måltidsinsulin, Fiasp®, godkendt i USA\n",
      "2017-09-29 CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia\n",
      "2017-09-29 CHMP støtter opdatering af indlægssedlen for Tresiba® i EU - ny indlægsseddel afspejler signifikant reduktion i risikoen for alvorlig hypoglykæmi\n",
      "2017-09-29 IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes\n",
      "2017-09-29 IDF og Novo Nordisk i samarbejde om den første globale undersøgelse om kendskabet til hjerte-kar-sygdom blandt mennesker med type 2-diabetes\n",
      "2017-09-15 Tresiba® studie viser, at mennesker med type 2-diabetes, som undgår alvorlig hypoglykæmi, har nedsat risiko for dødsfald\n",
      "2017-09-15 Tresiba® trial shows that people with type 2 diabetes who avoid severe hypoglycaemia have a reduced risk of death\n",
      "2017-09-13 Xultophy® reduces cardiovascular risk factors in people with type 2 diabetes\n",
      "2017-09-13 Xultophy® nedsætter hjerte-kar-relaterede risikofaktorer hos mennesker med type 2-diabetes\n",
      "2017-09-12 More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments\n",
      "2017-09-12 Flere opnår både blodsukker- og vægtreduktioner med semaglutid én gang ugentligt end med sammenlignende behandlinger\n",
      "2017-09-12 Fiasp® forbedrer den generelle blodsukkerregulering signifikant i type 1-diabetes på lang sigt\n",
      "2017-09-12 Fiasp® significantly improved overall blood sugar control in type 1 diabetes long-term\n",
      "2017-09-05 Novo Nordisk announces conclusion of US federal investigation of marketing practices\n",
      "2017-09-05 Novo Nordisk indgår forligsaftale i USA om markedsføringspraksis\n",
      "2017-08-25 Victoza® godkendt i USA som eneste behandling af type 2-diabetes med indikation til at nedsætte risikoen for alvorlige kardiovaskulære hændelser\n",
      "2017-08-25 Victoza® approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events\n",
      "2017-08-16 Semaglutid viser superioritet sammenlignet med dulaglutid med hensyn til blodsukkerkontrol og vægttab hos mennesker med type 2-diabetes i SUSTAIN 7\n",
      "2017-08-16 Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7\n",
      "2017-08-15 Ændringer i Novo Nordisks koncerndirektion\n",
      "2017-08-15 Changes in Novo Nordisk Executive Management\n",
      "2017-08-09 Novo Nordisk increased reported operating profit by 8% in the first six months of 2017\n",
      "2017-08-09 Novo Nordisks rapporterede resultat af primær drift steg med 8% i første halvår af 2017\n",
      "2017-07-27 Novo Nordisk A/S: Victoza® godkendt i EU som eneste GLP-1 med indlægsseddel, der omfatter forebyggelse af kardiovaskulære hændelser\n",
      "2017-07-27 Novo Nordisk A/S: Victoza® has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events\n",
      "2017-07-03 Novo Nordisk to present 35 abstracts at the International Society on Thrombosis and Haemostasis Congress\n",
      "2017-07-03 Novo Nordisk præsenterer 35 abstracts på den internationale hæmostasekongres ISTH\n",
      "2017-06-23 Novo Nordisk rapporterer op til 13,8% vægttab hos svært overvægtige mennesker i behandling med semaglutid i fase 2-studie\n",
      "2017-06-23 Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial\n",
      "2017-06-23 Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial\n",
      "2017-06-23 Novo Nordisk A/S: CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Victoza® i EU baseret på LEADER-studiet\n",
      "2017-06-22 Novo Nordisk A/S: CHMP støtter opdatering af indlægssedlen for Saxenda® i EU baseret på LEADER-studiet\n",
      "2017-06-22 Novo Nordisk A/S: CHMP endorses EU label update of Saxenda® based on the LEADER trial\n",
      "2017-06-20 Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes\n",
      "2017-06-20 Novo Nordisk får positiv 17-2 afstemning fra FDA's rådgivende komite om, at Victoza®  giver væsentlig dokumentation for nedsættelse af kardiovaskulær risiko hos mennesker med type 2-diabetes\n",
      "2017-06-16 FDA posts briefing materials prior to Advisory Committee meeting for Victoza® label update\n",
      "2017-06-16 FDA offentliggør briefingmateriale forud for møde i rådgivende komite om opdatering af indlægssedlen for Victoza®\n",
      "2017-06-14 Novo Nordisk indsender ansøgning i EU om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba®\n",
      "2017-06-14 Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label\n",
      "2017-06-12 Tresiba® viser ingen øget risiko for alvorlige kardiovaskulære hændelser samt signifikant reduktion i forekomsten af alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet\n",
      "2017-06-12 Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial\n",
      "2017-06-07 Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management\n",
      "2017-06-07 Lyfebulb og Novo Nordisk fortsætter samarbejdet om at fremme patientdrevet innovation indenfor diabetesbehandling\n",
      "2017-06-06 Refixia® (nonacog beta pegol; N9-GP) approved in the EU\n",
      "2017-06-06 Refixia® (nonacog beta pegol; N9-GP) godkendt i EU\n",
      "2017-05-31 Novo Nordisk får FDA-godkendelse for REBINYN® (nonacog beta pegol; N9-GP) i USA\n",
      "2017-05-31 Novo Nordisk receives US FDA approval of REBINYN® (nonacog beta pegol; N9-GP)\n",
      "2017-05-27 Novo Nordisk submits application in the US for including data from the DEVOTE trial in the Tresiba® label\n",
      "2017-05-27 Novo Nordisk indsender ansøgning i USA om inkludering af data fra DEVOTE-studiet i indlægssedlen for Tresiba®\n",
      "2017-05-17 Early response to Saxenda® resulted in weight maintenance and additional weight loss over 56 weeks\n",
      "2017-05-17 Tidlig respons på Saxenda® giver vægtvedligholdelse og yderligere vægttab over 56 uger\n",
      "2017-05-16 Change in composition of the Board of Directors of Novo Nordisk A/S\n",
      "2017-05-16 Ændring i sammensætningen af bestyrelsen for Novo Nordisk A/S\n",
      "2017-05-03 Novo Nordisks rapporterede resultat af primær drift steg med 10% i de første tre måneder af 2017\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2017-05-03 Novo Nordisk increased reported operating profit by 10% in the first three months of 2017\n",
      "2017-04-28 Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2017\n",
      "2017-04-28 Novo Nordisk A/S - Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 28. april 2017\n",
      "2017-04-21 Novo Nordisk A/S - Nedsættelse af aktiekapitalen\n",
      "2017-04-21 Novo Nordisk A/S - Reduction of the share capital\n",
      "2017-04-03 Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment\n",
      "2017-04-03 Én gang ugentlig semaglutid sænker konsistent blodsukker og vægt uanset baggrundsbehandling med diabeteslægemidler i tabletform\n",
      "2017-03-31 FDA offentliggør briefingmateriale forud for møde i rådgivende komite om nonacog beta pegol, langtidsvirkende faktor IX til behandling af hæmofili B\n",
      "2017-03-31 FDA posts briefing materials prior to Advisory Committee meeting for nonacog beta pegol, a long-acting factor IX for the treatment of haemophilia B\n",
      "2017-03-29 Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US\n",
      "2017-03-29 Novo Nordisk genindsender registreringsansøgningen for hurtigtvirkende insulin aspart i USA\n",
      "2017-03-24 Novo Nordisk receives positive opinion from the European regulatory authorities for Refixia® (nonacog beta pegol, N9-GP) for the treatment of haemophilia B\n",
      "2017-03-24 Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Refixia® (nonacog beta pegol, N9-GP) til behandling af hæmofili B\n",
      "2017-03-24 CHMP provides positive opinion for EU label update for Novo Nordisk's Tresiba® based on data from SWITCH trials\n",
      "2017-03-24 CHMP afgiver positiv udtalelse om opdatering af indlægssedlen for Novo Nordisks Tresiba® i EU baseret på data fra SWITCH-studierne\n",
      "2017-03-23 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2017-03-23 Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S\n",
      "2017-03-01 Ændring i Novo Nordisks koncerndirektion\n",
      "2017-03-01 Change in Novo Nordisk Executive Management\n",
      "2017-02-28 Novo Nordisk indsender registreringsansøgning for semaglutid til dosering én gang ugentligt til behandling af type 2-diabetes i Japan\n",
      "2017-02-28 Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan\n",
      "2017-02-24 Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S\n",
      "2017-02-24 Notice for the Annual General Meeting of  Novo Nordisk A/S\n",
      "2017-02-09 Novo Nordisk files annual report with the SEC\n",
      "2017-02-07 Novo Nordisk har udgivet sin årsrapport for 2016\n",
      "2017-02-07 Novo Nordisk publishes its 2016 Annual Report\n",
      "2017-02-02 Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016\n",
      "2017-02-02 Novo Nordisks resultat af primær drift, justeret, steg med 6% i lokale valutaer i 2016\n",
      "2017-01-30 Novo Nordisk indgår samarbejde med University of Oxford om type 2-diabetes og investerer 1 mia. kr. i nyt forskningscenter\n",
      "2017-01-30 Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre\n",
      "2017-01-10 Fiasp® (hurtigtvirkende insulin aspart) godkendt i Europa\n",
      "2017-01-10 Fiasp® (fast-acting insulin aspart) approved in Europe\n",
      "2017-01-09 Novo Nordisk and Glooko partner to develop digital health solutions for people with diabetes\n",
      "2017-01-09 Novo Nordisk og Glooko går sammen om at udvikle digitale sundhedsløsninger til mennesker med diabetes\n",
      "2016-12-05 Novo Nordisk indsender registreringsansøgning i USA og EU for semaglutid til dosering én gang ugentligt til behandling af type 2-diabetes\n",
      "2016-12-05 Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes\n",
      "2016-12-03 NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors\n",
      "2016-12-03 NovoSeven® standser 96,5% af blødningerne, når behandling iværksættes indenfor en time efter blødningens start hos mennesker med hæmofili A eller B med inhibitorer\n",
      "2016-11-29 Novo Nordisk A/S: Tresiba® viser en sikker kardiovaskulær profil og reducerer risikoen for alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet\n",
      "2016-11-29 Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial\n",
      "2016-11-21 Novo Nordisk receives US FDA approval for Xultophy® 100/3.6\n",
      "2016-11-21 Novo Nordisk får FDA-godkendelse for Xultophy® 100/3.6 i USA\n",
      "2016-11-14 Novo Nordisk forlænger og udvider program for børn med type 1-diabetes i udviklingslande\n",
      "2016-11-14 Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries\n",
      "2016-11-12 Tresiba® viser lavere dag-til-dag- og døgnvariation i blodsukkersænkende effekt sammenlignet med insulin glargin U300\n",
      "2016-11-12 Tresiba® demonstrated lower day-to-day and within-day variability in glucose-lowering effect compared with insulin glargine U300\n",
      "2016-11-11 Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Fiasp® (hurtigtvirkende insulin aspart) til behandling af diabetes\n",
      "2016-11-11 Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes\n",
      "2016-11-10 Novo Nordisk indsender ansøgning i EU om inkludering af data fra de to SWITCH-studier i indlægssedlen for Tresiba®\n",
      "2016-11-10 Novo Nordisk submits application in the EU for including data from the two SWITCH trials in Tresiba® label\n",
      "2016-11-03 Nyt studie viser, at kun 55% af svært overvægtige mennesker har fået en formel diagnose\n",
      "2016-11-03 New study showed that only 55% of people with obesity have received a formal obesity diagnosis\n",
      "2016-11-01 Nye data viser, at højt blodsukker efter måltiderne har negativ indvirkning på livskvaliteten for mennesker med diabetes\n",
      "2016-11-01 New data show post-meal hyperglycaemia is associated with a negative impact on quality of life for people with diabetes\n",
      "2016-10-28 Novo Nordisks resultat af primær drift, justeret, steg med 7% i lokale valutaer i de første ni måneder af 2016\n",
      "2016-10-28 Novo Nordisk increased adjusted operating profit by 7% in local currencies in the first nine months of 2016\n",
      "2016-10-25 Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza® label\n",
      "2016-10-25 Novo Nordisk indsender ansøgning til registreringsmyndighederne om inkludering af data fra LEADER-studiet i indlægssedlen for Victoza®\n",
      "2016-10-07 Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart\n",
      "2016-10-07 Novo Nordisk modtager Complete Response Letter i USA vedrørende hurtigerevirkende insulin aspart\n",
      "2016-09-29 Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees\n",
      "2016-09-29 Novo Nordisk annoncerer planer om at reducere medarbejderstaben med ca. 1.000 ansatte\n",
      "2016-09-23 Novo Nordisk indsender ansøgning i USA om inkludering af data fra de to SWITCH-studier i indlægssedlen for Tresiba®\n",
      "2016-09-23 Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba® label\n",
      "2016-09-16 Semaglutid reducerer forekomsten af alvorlige kardiovaskulære tilfælde med 26% hos voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom\n",
      "2016-09-16 Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk\n",
      "2016-09-15 Victoza® reducerer progressionen af nyreskade hos voksne med type 2-diabetes med høj risiko for hjerte-kar-sygdom\n",
      "2016-09-15 Victoza® lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk\n",
      "2016-09-14 Saxenda® giver konsistent vægttab og bedre blodsukkerregulering på tværs af BMI-kategorier efter tre års behandling\n",
      "2016-09-14 Saxenda® provides consistent weight loss and improvements in blood glucose control across BMI categories after three years of treatment\n",
      "2016-09-13 Semaglutid reducerer blodsukker signifikant bedre sammenlignet med placebo givet som tillægsbehandling til basalinsulin alene eller i kombination med metformin hos voksne med type 2-diabetes\n",
      "2016-09-13 Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone or with metformin in adults with type 2 diabetes\n",
      "2016-09-13 Voksne med type 2-diabetes i behandling med Xultophy® (IDegLira) har op til 4,5 gange så stor sandsynlighed for at opnå blodsukkerkontrol uden hypoglykæmi og vægtøgning sammenlignet med...\n",
      "2016-09-13 Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with...\n",
      "2016-09-13 Adults with type 2 diabetes treated with Xultophy® (IDegLira) were up to 4.5 times more likely to reach glycaemic targets without hypoglycaemia and weight gain vs up-titration with...\n",
      "2016-09-13 Voksne med type 2-diabetes i behandling med Xultophy® (IDegLira) har op til 4,5 gange så stor sandsynlighed for at opnå blodsukkerkontrol uden hypoglykæmi og vægtøgning sammenlignet med...\n",
      "2016-09-02 FDA extends regulatory review period for IDegLira by three months\n",
      "2016-09-02 FDA forlænger registreringsprocessen for IDegLira med tre måneder\n",
      "2016-09-01 Lars Rebien Sørensen stopper som administrerende direktør for Novo Nordisk; hans afløser bliver Lars Fruergaard Jørgensen\n",
      "2016-09-01 Lars Rebien Sørensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jørgensen appointed as successor\n",
      "2016-08-05 Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016\n",
      "2016-08-05 Novo Nordisks resultat af primær drift, justeret, steg med 8% i lokale valutaer i første halvår af 2016\n",
      "2016-07-11 Novo Nordisk to present 28 abstracts at the World Federation of Hemophilia Congress\n",
      "2016-07-04 Novo Nordisk investerer 400 mio. kr. i udbygning af produktionen i Kalundborg\n",
      "2016-07-04 Novo Nordisk invests DKK 400 million in an expanded production plant in Kalundborg\n",
      "2016-07-01 Novo Nordisk and Aarhus University team up on world-class talents\n",
      "2016-07-01 Novo Nordisk og Aarhus Universitet indgår samarbejde om talenter i verdensklasse\n",
      "2016-06-13 Victoza® significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial\n",
      "2016-06-13 Victoza® viser signifikant reduktion af risikoen for alvorlige kardiovaskulære hændelser og død hos voksne med type 2-diabetes i LEADER-studiet\n",
      "2016-06-13 Faster-acting insulin aspart showed a statistically significant reduction in HbA1c in type 1 diabetes and a comparable HbA1c reduction in type 2 diabetes versus NovoRapid® (insulin aspart)\n",
      "2016-06-13 Hurtigerevirkende insulin aspart viste en statistisk signifikant reduktion i HbA1c v. type 1-diabetes og sammenlignelig HbA1c-reduktion v. type 2-diabetes sammenlignet m. NovoRapid® (insulin aspart)\n",
      "2016-06-12 Semaglutid giver større forbedringer i glykæmisk kontrol sammenlignet med sitagliptin (SUSTAIN 2) og exenatid ER (SUSTAIN 3) i to kliniske studier med voksne med type 2-diabetes\n",
      "2016-06-12 Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes\n",
      "2016-06-12 Semaglutid giver større forbedringer i glykæmisk kontrol sammenlignet med sitagliptin (SUSTAIN 2) og exenatid ER (SUSTAIN 3) i to kliniske studier med voksne med type 2-diabetes\n",
      "2016-06-12 Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes\n",
      "2016-06-11 Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin  glargine U-100\n",
      "2016-06-11 Tresiba® (insulin degludec U-100) viser signifikant lavere forekomst af generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U-100\n",
      "2016-06-11 Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin  glargine U-100\n",
      "2016-06-11 Tresiba® (insulin degludec U-100) viser signifikant lavere forekomst af generel, natlig og alvorlig hypoglykæmi sammenlignet med insulin glargin U-100\n",
      "2016-06-06 Novo Nordisk to present 53 abstracts at 76th Annual American Diabetes Association Scientific Sessions in New Orleans, LA\n",
      "2016-06-02 Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors\n",
      "2016-06-02 Treårsdata for Saxenda® viser at tidlig respons kan forudsige forbedringer i vægttab og kardiometaboliske risikofaktorer\n",
      "2016-06-02 Three-year data show early response to Saxenda® resulted in improvements in weight loss and cardiometabolic risk factors\n",
      "2016-06-02 Treårsdata for Saxenda® viser at tidlig respons kan forudsige forbedringer i vægttab og kardiometaboliske risikofaktorer\n",
      "2016-05-27 Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes\n",
      "2016-05-27 Bedre blodsukkerregulering med semaglutid sammenlignet med insulin glargin U100 hos voksne med type 2-diabetes\n",
      "2016-05-27 Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes\n",
      "2016-05-27 Bedre blodsukkerregulering med semaglutid sammenlignet med insulin glargin U100 hos voksne med type 2-diabetes\n",
      "2016-05-24 IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee\n",
      "2016-05-24 FDA's rådgivende komite anbefaler godkendelse af IDegLira med stemmerne 16-0\n",
      "2016-05-20 FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide\n",
      "2016-05-20 FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid\n",
      "2016-05-16 Novo Nordisk indsender registreringsansøgning i USA for langtidsvirkende faktor IX til behandling af hæmofili B\n",
      "2016-05-16 Novo Nordisk files for regulatory approval in the US of long-acting factor IX for the treatment of haemophilia B\n",
      "2016-04-29 Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of 2016\n",
      "2016-04-29 Novo Nordisks resultat af primær drift, justeret, steg med 10% i lokale valutaer i det første kvartal af 2016\n",
      "2016-04-28 Novo Nordisk A/S - Total number of voting rights and share capital in Novo Nordisk A/S as of 28 April 2016\n",
      "2016-04-28 Novo Nordisk A/S - Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 28. april 2016\n",
      "2016-04-28 Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial\n",
      "2016-04-28 Semaglutid reducerer risikoen for alvorlige kardiovaskulære hændelser signifikant i SUSTAIN 6-studiet\n",
      "2016-04-21 Novo Nordisk plans to invest more than 100 million euros in production plants in Chartres, France\n",
      "2016-04-21 Novo Nordisk vil investere mere end 100 mio. euro i produktionsanlæg i Chartres, Frankrig\n",
      "2016-04-18 Novo Nordisk A/S - Nedsættelse af aktiekapitalen\n",
      "2016-04-18 Novo Nordisk A/S - Reduction of the share capital\n",
      "2016-04-08 Novo Nordisk A/S: Johannesburg Tilslutter Sig Cities Changing Diabetes\n",
      "2016-04-08 Novo Nordisk A/S: Johannesburg joins Cities Changing Diabetes\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2016-04-04 Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo\n",
      "2016-04-04 Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo\n",
      "2016-04-04 Behandling med Saxenda® i tre år giver signifikante forbedringer i kardiometaboliske risikofaktorer sammenlignet med placebo\n",
      "2016-04-04 Behandling med Saxenda® i tre år giver signifikante forbedringer i kardiometaboliske risikofaktorer sammenlignet med placebo\n",
      "2016-04-02 Victoza® (liraglutid 1,8 mg) reducerer langtidsblodsukkeret hos voksne med type 2-diabetes bedre, end hvis de fortsætter med sitagliptin\n",
      "2016-04-02 Victoza® (liraglutid 1,8 mg) reducerer langtidsblodsukkeret hos voksne med type 2-diabetes bedre, end hvis de fortsætter med sitagliptin\n",
      "2016-04-02 Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment\n",
      "2016-04-02 Victoza® (liraglutide 1.8 mg) provided superior HbA1c reductions in adults with type 2 diabetes compared to continued sitagliptin treatment\n",
      "2016-04-02 Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes\n",
      "2016-04-02 Semaglutid viser større forbedringer i reguleringen af blodsukkeret end placebo hos voksne med type 2-diabetes\n",
      "2016-04-02 Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes\n",
      "2016-04-02 Semaglutid viser større forbedringer i reguleringen af blodsukkeret end placebo hos voksne med type 2-diabetes\n",
      "2016-03-29 Første spadestik taget til ny fabrik til 2 mia. dollars i Clayton, USA\n",
      "2016-03-29 Novo Nordisk breaks ground on USD 2bn production facility in Clayton, North Carolina\n",
      "2016-03-18 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2016-03-18 Beslutninger på den ordinære generalforsamling i  Novo Nordisk A/S\n",
      "2016-03-04 Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial\n",
      "2016-03-04 Victoza® reducerer risikoen for alvorlige kardiovaskulære hændelser signifikant i LEADER-studiet\n",
      "2016-02-23 Novo Nordisk afslutter med succes det femte fase 3a-studie med semaglutid i mennesker med type 2-diabetes\n",
      "2016-02-23 Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes\n",
      "2016-02-23 Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes\n",
      "2016-02-23 Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin U100 i blindet fase 3b-studie i mennesker med type 1-diabetes\n",
      "2016-02-23 Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S\n",
      "2016-02-23 Notice for the Annual General Meeting of  Novo Nordisk A/S\n",
      "2016-02-12 Proposed changes in composition of the Board of Directors of Novo Nordisk A/S\n",
      "2016-02-12 Foreslåede ændringer i sammensætningen af bestyrelsen i Novo Nordisk A/S\n",
      "2016-02-10 Novo Nordisk files annual report with the SEC\n",
      "2016-02-08 Novo Nordisk publishes its 2015 Annual Report\n",
      "2016-02-08 Novo Nordisk har udgivet sin årsrapport for 2015\n",
      "2016-02-03 Novo Nordisk increased operating profit by 43% in 2015 to DKK 49.4 billion\n",
      "2016-02-03 Novo Nordisks resultat af primær drift steg med 43% i 2015 til 49,4 mia. kr.\n",
      "2016-01-29 Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes\n",
      "2016-01-29 Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin i blindet fase 3b-studie i mennesker med type 2-diabetes\n",
      "2016-01-07 Novo Nordisk files for regulatory approval of long-acting factor IX in the EU for the treatment of haemophilia B\n",
      "2016-01-07 Novo Nordisk indsender registreringsansøgning i EU for langtidsvirkende faktor IX til behandling af hæmofili B\n",
      "2015-12-18 Novo Nordisk i partnerskab med C40 om at forbedre miljø og sundhed i byerne\n",
      "2015-12-18 Novo Nordisk and C40 partner to improve environment and health in cities\n",
      "2015-12-17 Novo Nordisk afslutter med succes det fjerde fase 3a-studie med semaglutid til behandling af type 2-diabetes\n",
      "2015-12-17 Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes\n",
      "2015-12-10 Novo Nordisk indgår samarbejde med IBM om diabetesløsninger baseret på Watson Health Cloud\n",
      "2015-12-10 Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud\n",
      "2015-12-09 Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes\n",
      "2015-12-09 Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i USA til behandling af type 1- og type 2-diabetes\n",
      "2015-12-04 Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the EU for the treatment of type 1 and 2 diabetes\n",
      "2015-12-04 Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i EU til behandling af type 1- og type 2-diabetes\n",
      "2015-12-01 Nye data viser, hvorfor type 2-diabetikere, som er utilstrækkeligt reguleret med basalinsulin, og læger tøver med at intensivere insulinbehandlingen\n",
      "2015-12-01 New data reveal why physicians and people with type 2 diabetes uncontrolled on basal insulin are reluctant to intensify insulin therapy\n",
      "2015-12-01 New data highlight impact of post-meal hyperglycaemia on people with diabetes\n",
      "2015-11-24 Alle Novo Nordisks fabrikker skal producere på vedvarende energi i 2020\n",
      "2015-11-24 All Novo Nordisk production plants to run on renewable power in 2020\n",
      "2015-11-18 Novo Nordisks kapitalmarkedsdag 2015\n",
      "2015-11-18 Highlights to be presented at Novo Nordisk's Capital Markets Day 2015\n",
      "2015-11-16 Novo Nordisk og Københavns Kommune bag ny forskning, der kræver nytænkning af diabetesindsatsen\n",
      "2015-11-16 International study prompts rethink on the rise of diabetes in cities\n",
      "2015-11-04 Novo Nordisk investerer 2,1 mia. kr. i ny insulinfylde-fabrik i Hillerød og skaber 450 nye arbejdspladser\n",
      "2015-11-04 Novo Nordisk invests DKK 2.1 billion in new insulin filling facility in Denmark, creating 450 new jobs\n",
      "2015-11-03 Novo Nordisk og University of Washington indgår samarbejde om forskning i hjernens rolle i regulering af blodsukker og fedme\n",
      "2015-11-03 Novo Nordisk and University of Washington to collaborate on exploring the role of the brain in regulating blood glucose and obesity\n",
      "2015-10-29 Novo Nordisks resultat af primær drift steg med 51% i de første ni måneder af 2015 til 38,3 mia. kr.\n",
      "2015-10-29 Novo Nordisk increased operating profit by 51% in the first nine months of 2015 to DKK 38.3 billion\n",
      "2015-09-25 Novo Nordisk receives US FDA approval for Tresiba® and Ryzodeg® 70/30\n",
      "2015-09-25 Novo Nordisk får FDA-godkendelse for Tresiba® og Ryzodeg® 70/30 i USA\n",
      "2015-09-25 Novo Nordisk successfully completes second phase 3a trial with semaglutide in people with type 2 diabetes\n",
      "2015-09-25 Novo Nordisk afslutter med succes det andet fase 3a-studie med semaglutid til behandling af type 2-diabetes\n",
      "2015-09-22 Novo Nordisk and the Food and Drug Administration of the Islamic Republic of Iran sign memorandum of understanding to build manufacturing facility in Iran\n",
      "2015-09-22 Novo Nordisk og de iranske sundhedsmyndigheder underskriver hensigtserklæring om byggeri af fabrik i Iran\n",
      "2015-09-15 New study shows different perceptions of control among physicians and patients may lead to suboptimal type 2 diabetes management\n",
      "2015-09-15 Nyt studie viser, at type 2-diabetes ikke behandles optimalt, fordi læger og patienter ikke deler opfattelsen af, hvad god blodsukkerkontrol er\n",
      "2015-09-07 Novo Nordisk and MIT to collaborate on researching the next generation of drug delivery devices\n",
      "2015-09-07 Novo Nordisk og MIT indleder samarbejde om forskning i næste generation af doseringssystemer til lægemidler\n",
      "2015-09-03 Novo Nordisk invests DKK 500 million in a new raw material warehouse in Denmark\n",
      "2015-09-03 Novo Nordisk investerer 500 mio. kr. i nyt råvarelager i Hillerød\n",
      "2015-08-27 Novo Nordisk to acquire Calibrium LLC and MB2 LLC\n",
      "2015-08-27 Novo Nordisk køber Calibrium LLC og MB2 LLC\n",
      "2015-08-26 Novo Nordisk planlægger at investere 2 mia. dollars i nye fabrikker i USA og Danmark\n",
      "2015-08-26 Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark\n",
      "2015-08-26 Novo Nordisk to initiate phase 3a development of oral semaglutide, a once-daily oral GLP-1 analogue\n",
      "2015-08-26 Novo Nordisk påbegynder fase 3a-udvikling af oral semaglutid, en GLP-1-analog i tabletform til dosering én gang dagligt\n",
      "2015-08-24 Novo Nordisk afslutter andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin ved behandling af type 1-diabetes (NN9211)\n",
      "2015-08-24 Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211)\n",
      "2015-08-06 Novo Nordisk increased operating profit in Danish kroner by 57% in the first six months of 2015 to DKK 26.3 billion\n",
      "2015-08-06 Novo Nordisks resultat af primær drift opgjort i kroner steg med 57% i første halvår af 2015 til 26,3 mia. kr.\n",
      "2015-07-28 Team Novo Nordisk, the world's first all-diabetes professional cycling team, to race in Post Danmark Rundt for third consecutive year\n",
      "2015-07-28 Team Novo Nordisk stiller for tredje år i træk til start i Post Danmark Rundt\n",
      "2015-07-10 Novo Nordisk afslutter med succes det første fase 3a-studie med semaglutid til type 2-diabetes\n",
      "2015-07-10 Novo Nordisk successfully completes first phase 3a trial with semaglutide in people with type 2 diabetes\n",
      "2015-05-29 Novo Nordisk og Københavns Universitet sætter  blus på udveksling af talentstuderende\n",
      "2015-05-29 Novo Nordisk and the University of Copenhagen to boost exchange of talented students\n",
      "2015-05-20 Janssen Biotech Inc. acquires licence from Novo Nordisk for a development programme focused on autoimmune diseases\n",
      "2015-05-20 Janssen Biotech Inc. får licens fra Novo Nordisk til et udviklingsprogram, der fokuserer på autoimmune sygdomme\n",
      "2015-05-04 Novo Nordisk investerer 1,5 mia. kr. i ny fabrik i Kalundborg til produktion af blødermedicin\n",
      "2015-05-04 Novo Nordisk invests DKK 1.5 billion in new haemophilia treatment manufacturing facility in Denmark\n",
      "2015-04-30 Novo Nordisks resultat af primær drift i kroner steg med 73% i første kvartal af 2015 til 13,9 mia. kr.\n",
      "2015-04-30 Increased operating profit in Danish kroner by 73% in the first quarter of 2015 to DKK 13.9 billion\n",
      "2015-04-29 Total number of voting rights and share capital in Novo Nordisk A/S as of 29 April 2015\n",
      "2015-04-29 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 29. april 2015\n",
      "2015-04-22 United States first country to launch Saxenda®\n",
      "2015-04-22 USA bliver første land, der lancerer Saxenda®\n",
      "2015-04-22 Novo Nordisk A/S - Nedsættelse af aktiekapitalen\n",
      "2015-04-22 Novo Nordisk A/S - Reduction of the share capital\n",
      "2015-04-14 Novo Nordisk extends programme for children with diabetes in developing countries\n",
      "2015-04-14 Novo Nordisk forlænger program for børn med diabetes i udviklingslande\n",
      "2015-04-10 Novo Nordisk opens new insulin formulation and filling facility in Russia\n",
      "2015-04-10 Novo Nordisk åbner ny fabrik til formulering og påfyldning af insulin i Rusland\n",
      "2015-04-07 Novo Nordisk A/S: Amerikanske FDA accepterer at behandle genindsendelserne af Tresiba® og Ryzodeg®\n",
      "2015-04-07 US FDA accepts Tresiba® and Ryzodeg® resubmissions for review\n",
      "2015-03-26 Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US\n",
      "2015-03-26 Novo Nordisk har besluttet at genindsende registreringsansøgningerne for Tresiba® og Ryzodeg® i USA\n",
      "2015-03-26 Novo Nordisk has decided to resubmit the New Drug Applications of Tresiba® and Ryzodeg® in the US\n",
      "2015-03-26 Novo Nordisk har besluttet at genindsende registreringsansøgningerne for Tresiba® og Ryzodeg® i USA\n",
      "2015-03-25 Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes\n",
      "2015-03-25 Novo Nordisk A/S : Novo Nordisk afslutter fase 3a-studier, der sammenligner hurtigerevirkende insulin aspart med NovoRapid® i type 1- og type 2-diabetes\n",
      "2015-03-23 Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity\n",
      "2015-03-23 Novo Nordisk A/S: Saxenda® godkendt i Europa til behandling af fedme\n",
      "2015-03-19 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2015-03-19 Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S\n",
      "2015-03-08 Nye data for svært overvægtige voksne eller overvægtige voksne med vægtrelaterede komplikationer, der taber sig mindst 5% med Saxenda®, viser forbedringer i ...\n",
      "2015-03-08 New data in adults with obesity - or who are overweight with comorbidities losing at least 5% body weight with Saxenda® showed improvement in blood glucose, CV risk factors and quality of life outc...\n",
      "2015-03-06 Novo Nordisk A/S gennemfører succesfuld børsnotering af NNIT A/S\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2015-03-06 Novo Nordisk successfully completes Initial Public Offering of NNIT A/S\n",
      "2015-03-02 Novo Nordisk forhøjer det indikative udbudskursinterval for børsnoteringen af NNIT A/S\n",
      "2015-03-02 Novo Nordisk increases indicative offer price range for the initial public offering of NNIT A/S\n",
      "2015-02-23 Novo Nordisk A/S fastsætter indikativt kursinterval for den påtænkte børsnotering af NNIT A/S\n",
      "2015-02-23 Novo Nordisk A/S sets indicative price range for the contemplated IPO of NNIT A/S\n",
      "2015-02-20 Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes\n",
      "2015-02-20 Novo Nordisk annoncerer positive resultater af fase 2-studie med tabletformulering af semaglutid til type 2-diabetes\n",
      "2015-02-20 Novo Nordisk A/S: Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S\n",
      "2015-02-20 Notice for the Annual General Meeting of  Novo Nordisk A/S\n",
      "2015-02-10 Novo Nordisk og Karolinska Institutet indgår samarbejde indenfor diabetes\n",
      "2015-02-10 Novo Nordisk and Karolinska Institutet join forces in the field of diabetes\n",
      "2015-02-09 Novo Nordisk A/S søger børsnotering af NNIT A/S\n",
      "2015-02-09 Novo Nordisk A/S seeks an initial public offering of NNIT\n",
      "2015-02-05 Novo Nordisk files annual report with the SEC\n",
      "2015-02-03 Novo Nordisk har udgivet sin årsrapport for 2014\n",
      "2015-02-03 Novo Nordisk publishes its 2014 Annual Report\n",
      "2015-01-30 Novo Nordisks resultat af primær drift i lokale valutaer steg med 13% i 2014\n",
      "2015-01-30 Novo Nordisk increased operating profit in local currencies by 13% in 2014\n",
      "2015-01-22 Novo Nordisk receives positive opinion from the European regulatory authorities for Saxenda® (liraglutide 3 mg) for the treatment of obesity\n",
      "2015-01-22 Novo Nordisk får positiv udtalelse fra de europæiske registreringsmyndigheder for Saxenda® (liraglutid 3 mg) til behandling af fedme\n",
      "2014-12-23 Novo Nordisk receives FDA approval for Saxenda® for the treatment of obesity\n",
      "2014-12-23 Novo Nordisk får FDA-godkendelse for Saxenda® til behandling af fedme\n",
      "2014-12-19 Tresiba® receives positive opinion from CHMP for treatment of children with diabetes\n",
      "2014-12-19 Tresiba® (insulin degludec) får positiv udtalelse fra CHMP til behandling af børn med diabetes\n",
      "2014-12-07 Fase 3-data for NovoEight® viser, at frekvensen af blødninger reduceres over tid hos mennesker med hæmofili A\n",
      "2014-12-07 NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with haemophilia A\n",
      "2014-11-24 Ændringer i Novo Nordisks koncerndirektion\n",
      "2014-11-24 Changes in Novo Nordisk's Executive Management\n",
      "2014-11-21 Victoza® (liraglutid) får positiv udtalelse fra CHMP for anvendelse til voksne med type 2-diabetes og moderat nedsat nyrefunktion\n",
      "2014-11-21 Victoza® receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal impairment\n",
      "2014-11-17 Novo Nordisk andenbedst i verden til at sikre adgang til medicin\n",
      "2014-11-17 Novo Nordisk second best in the world at providing access to medicine\n",
      "2014-11-14 Tianjin og Shanghai tilslutter sig Cities Changing Diabetes på Verdensdiabetesdagen\n",
      "2014-11-14 Tianjin and Shanghai join Cities Changing Diabetes on World Diabetes Day\n",
      "2014-11-04 New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2%\n",
      "2014-11-04 Nye fase 3a-data viser, at ni ud af 10 svært overvægtige voksne tabte sig med liraglutid 3 mg, og deltagere, der gennemførte studiet, tabte sig i gennemsnit 9,2%\n",
      "2014-11-03 Novo Nordisk og Roche Diabetes Care lancerer ny behandlingsmulighed til insulinpumper\n",
      "2014-11-03 Novo Nordisk and Roche Diabetes Care launch new treatment option to simplify insulin pump therapy\n",
      "2014-11-03 Novo Nordisk: Houston tilslutter sig Cities Changing Diabetes\n",
      "2014-11-03 Novo Nordisk: City of Houston and Novo Nordisk partner to lead fight against urban diabetes epidemic\n",
      "2014-10-31 Novo Nordisk investerer 750 millioner kroner i nye laboratorier til diabetesforskning i Danmark\n",
      "2014-10-31 Novo Nordisk invests DKK 750 million in new laboratories for diabetes research in Denmark\n",
      "2014-10-30 Resultat af primær drift opgjort i lokale valutaer steg med 11% i de første ni måneder af 2014\n",
      "2014-10-30 Increased operating profit in local currencies by 11% in the first nine months of 2014\n",
      "2014-10-24 Novo Nordisk modtager begæring om udlevering af dokumenter i USA\n",
      "2014-10-24 Novo Nordisk receives subpoena from US Attorney\n",
      "2014-10-17 Novo Nordisk verdens anden bedste forsknings-arbejdsplads\n",
      "2014-10-17 Novo Nordisk second best science employer in the world\n",
      "2014-09-25 Novo Nordisk etablerer ny enhed for fedmeforskning i Seattle\n",
      "2014-09-25 Novo Nordisk establishes new obesity research unit in Seattle\n",
      "2014-09-18 Xultophy® (IDegLira) godkendt i Europa\n",
      "2014-09-18 Xultophy® (IDegLira) approved in Europe\n",
      "2014-09-18 Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen\n",
      "2014-09-18 Ryzodeg® giver god blodsukkerregulering med færre injektioner end basal-bolusbehandling\n",
      "2014-09-16 New data show long-term efficacy and safety of Tresiba® in children and adolescents with type 1 diabetes\n",
      "2014-09-16 Nye data viser langsigtet effekt og sikkerhed for Tresiba® hos børn og unge med type 1-diabetes\n",
      "2014-09-11 Saxenda® for the treatment of obesity receives positive 14-1 vote in favour of approval from FDA Advisory Committee\n",
      "2014-09-11 FDA's rådgivende komite anbefaler godkendelse af Saxenda® til behandling af fedme med stemmerne 14-1\n",
      "2014-09-09 FDA posts briefing materials prior to Advisory Committee meeting for Saxenda® for the treatment of obesity\n",
      "2014-09-09 FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om Saxenda® til behandling af fedme\n",
      "2014-09-02 Novo Nordisk indstiller aktiviteterne indenfor inflammatoriske sygdomme\n",
      "2014-09-02 Novo Nordisk discontinues its activities within inflammatory disorders\n",
      "2014-09-01 Ryzodeg® lanceres i Mexico som første land\n",
      "2014-09-01 Mexico first country to launch Ryzodeg®\n",
      "2014-08-27 Novo Nordisk køber fabrik i New Hampshire, USA\n",
      "2014-08-27 Novo Nordisk buys production plant in New Hampshire\n",
      "2014-08-18 Novo Nordisk A/S : Press release test\n",
      "2014-08-18 Novo Nordisk A/S : Press release test\n",
      "2014-08-07 Novo Nordisks resultat af primær drift opgjort i lokale valutaer steg med 12% i første halvår af 2014\n",
      "2014-08-07 Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014\n",
      "2014-07-25 Novo Nordisk modtager positiv udtalelse om Xultophy® (IDegLira) fra de europæiske registreringsmyndigheder\n",
      "2014-07-25 Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities\n",
      "2014-05-20 FDA berammer møde i rådgivende komite om liraglutid 3 mg til behandling af fedme\n",
      "2014-05-20 FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity\n",
      "2014-05-01 Novo Nordisks resultat af primær drift opgjort i lokale valutaer steg med 15% i første kvartal af 2014\n",
      "2014-05-01 Increased operating profit in local currencies by 15% in the first quarter of 2014\n",
      "2014-04-30 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2014\n",
      "2014-04-30 Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2014\n",
      "2014-04-23 Reduction of the share capital\n",
      "2014-04-23 Nedsættelse af aktiekapitalen\n",
      "2014-03-21 Den langsigtede aktiebaserede incitamentsordning for Novo Nordisks Senior Management Board for 2014\n",
      "2014-03-21 2014 long-term, share based incentive programme for Novo Nordisk's  Senior Management Board\n",
      "2014-03-20 Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S\n",
      "2014-03-20 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2014-03-19 Positive resultater fra det første fase 3-studie med N8-GP, en langtidsvirkende faktor VIII til behandling af hæmofili A\n",
      "2014-03-19 Positive results from first phase 3 trial with N8-GP, a long-acting factor VIII for treatment of haemophilia A\n",
      "2014-02-27 Election of employee representatives to the Board of Directors of Novo Nordisk A/S\n",
      "2014-02-27 Valg af medarbejderrepræsentanter til bestyrelsen i Novo Nordisk A/S\n",
      "2014-02-21 Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S\n",
      "2014-02-21 Novo Nordisk A/S : Notice for the Annual General Meeting of  Novo Nordisk A/S\n",
      "2014-01-30 Novo Nordisks resultat af primær drift i lokale valutaer steg med 15% i 2013\n",
      "2014-01-30 Novo Nordisk increased operating profit in local currencies by 15% in 2013\n",
      "2013-12-20 Novo Nordisk indsender registreringsansøgning for liraglutid 3 mg til behandling af fedme\n",
      "2013-12-20 Novo Nordisk files for regulatory approval of liraglutide  3 mg for the treatment of obesity\n",
      "2013-12-10 Information om aktiesplit\n",
      "2013-12-10 Stock split information\n",
      "2013-12-03 Hovedpunkter fra Novo Nordisks kapitalmarkedsdag 2013\n",
      "2013-12-03 Highlights from Novo Nordisk's Capital Markets Day 2013\n",
      "2013-10-31 Novo Nordisks resultat af primær drift steg med 10% i de første ni måneder af 2013\n",
      "2013-10-31 Novo Nordisk Increased operating profit by 10% in the first nine months of 2013\n",
      "2013-08-08 Novo Nordisk increased operating profit by 15% in the first six months of 2013\n",
      "2013-08-08 Novo Nordisks resultat af primær drift steg med 15% i første halvår af 2013\n",
      "2013-06-18 Federal Circuit Court rules on patent litigation involving Prandin® (repaglinide)\n",
      "2013-06-18 Federal Circuit Court afsiger dom i patentsag om Prandin® (repaglinid)\n",
      "2013-05-31 Novo Nordisk files for regulatory approval of IDegLira in the EU for the treatment of type 2 diabetes\n",
      "2013-05-31 Novo Nordisk indsender registreringsansøgning for IDegLira i EU til behandling af type 2-diabetes\n",
      "2013-05-23 Novo Nordisk rapporterer 8% vægttab i fase 3a-fedmestudie med liraglutid 3 mg\n",
      "2013-05-23 Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg\n",
      "2013-05-17 Novo Nordisk reports positive results from first phase 3 trial with long-acting factor IX for treatment of haemophilia B\n",
      "2013-05-17 Novo Nordisk rapporterer positive resultater fra det første fase 3-studie med langtidsvirkende faktor IX til behandling af hæmofili B\n",
      "2013-05-01 Increased operating profit by 18% in the first quarter of 2013\n",
      "2013-05-01 Resultat af primær drift steg med 18% i første kvartal af 2013\n",
      "2013-04-30 Novo Nordisk A/S : Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2013\n",
      "2013-04-30 Novo Nordisk A/S : det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2013\n",
      "2013-04-22 Reduction of the share capital\n",
      "2013-04-22 Nedsættelse af aktiekapitalen\n",
      "2013-03-21 2013 long-term, share based incentive programme for the Senior Management Board\n",
      "2013-03-21 Den langsigtede aktiebaserede incitamentsordning for Senior Management Board for 2013\n",
      "2013-03-20 Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2013-03-20 Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S\n",
      "2013-03-18 People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial\n",
      "2013-03-18 Type 2-diabetikere opnår 6% vægttab med liraglutid 3 mg i fase 3a-fedmestudie\n",
      "2013-02-22 Notice for the Annual General Meeting of  Novo Nordisk A/S\n",
      "2013-02-22 Indkaldelse til ordinær generalforsamling i  Novo Nordisk A/S\n",
      "2013-02-10 Novo Nordisk modtager Complete Response Letter i USA vedrørende Tresiba® og Ryzodeg®\n",
      "2013-02-10 Novo Nordisk receives Complete Response Letter in the US for Tresiba® and Ryzodeg®\n",
      "2013-02-07 Press release: Novo Nordisk files annual report with the SEC\n",
      "2013-02-05 Previously announced FDA Warning Letter published\n",
      "2013-02-05 Det tidligere omtalte Warning Letter fra FDA publiceret\n",
      "2013-01-31 Novo Nordisk increased operating profit by 32% in 2012\n",
      "2013-01-31 Novo Nordisks resultat af primær drift steg med 32% i 2012\n",
      "2013-01-21 Tresiba® and Ryzodeg® receive marketing authorisations in Europe\n",
      "2013-01-21 Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa\n",
      "2012-12-25 Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan\n",
      "2012-12-25 Ryzodeg® (insulin degludec/insulin aspart) approved in Japan\n",
      "2012-12-19 The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development\n",
      "2012-12-19 Det sidste fase 3a-studie for IDegLira afsluttet, og FIAsp godkendt til fase 3-udvikling\n",
      "2012-12-03 Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite\n",
      "2012-12-03 Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan\n",
      "2012-11-08 Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee\n",
      "2012-11-08 Positiv afstemning i FDA's rådgivende komite vedrørende godkendelse af insulin degludec og insulin degludec/ insulin aspart\n",
      "2012-11-06 FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart\n",
      "2012-11-06 FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart\n",
      "2012-10-31 Novo Nordisks resultat af primær drift steg med 34% i de første ni måneder af 2012\n",
      "2012-10-31 Novo Nordisk increased operating profit by 34% in the first nine months of 2012\n",
      "2012-10-25 FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart\n",
      "2012-10-25 FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart\n",
      "2012-10-19 Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities\n",
      "2012-10-19 Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder\n",
      "2012-10-18 Japansk lægemiddelagentur offentliggør evalueringsrapport om Tresiba®\n",
      "2012-10-18 Japan's Pharmaceuticals and Medical Devices Agency publishes assessment report of Tresiba®\n",
      "2012-09-28 Novo Nordisk A/S: Novo Nordisk indstiller udviklingen af vatreptacog alfa efter analyse af fase 3-resultater\n",
      "2012-09-28 Novo Nordisk A/S: Novo Nordisk discontinues development of vatreptacog alfa following analysis of phase 3 results\n",
      "2012-09-28 Novo Nordisk A/S: Tresiba® (insulin degludec) godkendt i Japan\n",
      "2012-09-28 Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan\n",
      "2012-08-31 Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2012-08-31 Novo Nordisk A/S : Insulin degludec passerer evalueringen i japansk medicinkomite\n",
      "2012-08-09 Novo Nordisk increased operating profit by 31% in the first half of 2012\n",
      "2012-08-09 Novo Nordisk A/S: Novo Nordisks resultat af primær drift steg med 31% i første halvår af 2012\n",
      "2012-07-18 Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart\n",
      "2012-07-18 Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart\n",
      "2012-06-21 Novo Nordisk påbegynder fase 3-udvikling af  GLP-1-analogen semaglutid til brug en gang om ugen\n",
      "2012-06-21 Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue\n",
      "2012-06-08 Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder\n",
      "2012-06-08 Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months\n",
      "2012-04-30 Novo Nordisk A/S: Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. april 2012\n",
      "2012-04-30 Novo Nordisk A/S: Total number of voting rights and share capital in Novo Nordisk A/S as of 30 April 2012\n",
      "2012-04-27 Novo Nordisk A/S forventer at vælge ny formand i 2013\n",
      "2012-04-27 Novo Nordisk A/S expects to elect new chairman in 2013\n",
      "2012-04-27 Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012\n",
      "2012-04-27 Novo Nordisk A/S: Resultat af primær drift steg med 18% i første kvartal af 2012\n",
      "2012-04-23 Novo Nordisk A/S :  Novo Nordisk A/S - Reduction of the share capital\n",
      "2012-04-23 Novo Nordisk A/S : Novo Nordisk A/S - Nedsættelse af aktiekapitalen\n",
      "2012-04-17 Novo Nordisk A/S: Højesteretskendelse i USA giver Caraco Pharmaceutical mulighed for at gøre indsigelse mod Novo Nordisks patent på Prandin® (repaglinid)\n",
      "2012-04-17 Novo Nordisk A/S: US Supreme Court ruling allows Caraco Pharmaceutical to challenge Novo Nordisk's patent submissions for Prandin® (repaglinide)\n",
      "2012-04-06 Indlægsseddel for Victoza® i USA opdateret med data, som viser, at Victoza® virker bedre end Januvia®\n",
      "2012-04-06 Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia®\n",
      "2012-03-21 Novo Nordisk A/S: Beslutninger på den ordinære generalforsamling i Novo Nordisk A/S\n",
      "2012-03-21 Novo Nordisk A/S: Resolutions from the Annual General Meeting of Novo Nordisk A/S\n",
      "2012-02-23 Novo Nordisk A/S: Indkaldelse til ordinær generalforsamling i Novo Nordisk A/S\n",
      "2012-02-23 Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2012-02-08 Novo Nordisk files annual report with the SEC\n",
      "2012-02-02 Novo Nordisk increased operating profit by 18% in 2011\n",
      "2012-02-02 Novo Nordisks resultat af primær drift steg med 18% i 2011\n",
      "2011-12-22 Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan\n",
      "2011-12-22 Novo Nordisk indsender registreringsansøgning for den ultralangtidsvirkende insulinanalog, Degludec, i Japan\n",
      "2011-11-07 Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes\n",
      "2011-11-07 Novo Nordisk A/S: DegludecPlus giver bedre blodsukkerregulering end insulin glargin i et fase 3a-studie med japanske type 2-diabetikere\n",
      "2011-10-27 Novo Nordisk A/S: Interim financial report for the period 1 January 2011 to 30 September 2011\n",
      "2011-10-27 Novo Nordisk A/S: Delårsrapport for perioden 1. januar til 30. september 2011\n",
      "2011-09-29 Novo Nordisk indsender registreringsansøgning for de ultralangtidsvirkende insulinpræparater Degludec og DegludecPlus i USA\n",
      "2011-09-29 Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in the US\n",
      "2011-09-26 Novo Nordisk indsender registreringsansøgning for de ultralangtidsvirkende insulinpræparater Degludec og DegludecPlus i Europa\n",
      "2011-09-26 Novo Nordisk files for regulatory approval of the ultra-long-acting insulins Degludec and DegludecPlus in Europe\n",
      "2011-08-04 Novo Nordisk increased operating profit by 13% in the first six months of 2011\n",
      "2011-08-04 Novo Nordisks resultat af primær drift steg med 13%  i første halvår af 2011\n",
      "2011-06-10 Novo Nordisk Inc. indgår forlig med det amerikanske justitsministerium\n",
      "2011-06-10 Novo Nordisk Inc. reaches agreements with US Department of Justice\n",
      "2011-05-31 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 31. maj 2011\n",
      "2011-05-31 Total number of voting rights and share capital in Novo Nordisk A/S as of 31 May 2011\n",
      "2011-05-05 Hovedpunkter fra Novo Nordisks kapitalmarkedsdag 2011\n",
      "2011-05-05 Highlights from Novo Nordisk's Capital Markets Day 2011\n",
      "2011-05-02 Novo Nordisk A/S - Nedsættelse af aktiekapitalen\n",
      "2011-05-02 Novo Nordisk A/S - Reduction of the share capital\n",
      "2011-04-28 Novo Nordisks resultat af primær drift steg med 24%  i første kvartal af 2011\n",
      "2011-04-28 Novo Nordisk increased operating profit by 24% in the first quarter of 2011\n",
      "2011-03-23 Beslutninger fra den ordinære generalforsamling i  Novo Nordisk A/S\n",
      "2011-03-23 Resolutions from the Annual General Meeting at Novo Nordisk A/S\n",
      "2011-03-15 Novo Nordisk opnår godkendelse af Victoza® i Kina\n",
      "2011-03-15 Novo Nordisk receives approval for Victoza® in China\n",
      "2011-02-26 Notice for the Annual General Meeting of Novo Nordisk A/S\n",
      "2011-02-26 Ordinær generalforsamling i Novo Nordisk A/S\n",
      "2011-02-16 Novo Nordisk har modtaget begæring om udlevering af dokumenter i USA\n",
      "2011-02-16 Novo Nordisk receives subpoena in the US\n",
      "2011-02-02 Novo Nordisk increased operating profit by 27% in 2010\n",
      "2011-02-02 Novo Nordisks resultat af primær drift steg med 27% i 2010\n",
      "2011-01-19 Novo Nordisk intends to appeal adverse ruling in Prandin® (repaglinide) patent case\n",
      "2011-01-19 Novo Nordisk forventer at anke kendelse i amerikansk patentsag om Prandin® (repaglinid)\n",
      "2010-12-22 Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies\n",
      "2010-12-22 Degludec giver væsentligt nedsat risiko for natlig hypoglykæmi sammenlignet med insulin glargin i to langtidsstudier\n",
      "2010-10-28 Interim financial report for the period 1 January 2010 to 30 September 2010\n",
      "2010-10-28 Delårsrapport for perioden 1. januar 2010 til 30. september 2010\n",
      "2010-10-08 Novo Nordisk completes divestment of ZymoGenetics, Inc.\n",
      "2010-10-08 Novo Nordisks salg af ZymoGenetics, Inc. gennemført\n",
      "2010-09-07 Novo Nordisk divests its ownership of ZymoGenetics, Inc.\n",
      "2010-09-07 Novo Nordisk sælger ejerandel i ZymoGenetics, Inc.\n",
      "2010-08-05 Delårsrapport for perioden 1. januar 2010 til 30. juni 2010\n",
      "2010-08-05 Interim financial report for the period 1 January 2010 to 30 June 2010\n",
      "2010-06-30 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. juni 2010\n",
      "2010-06-30 Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2010\n",
      "2010-06-22 Novo Nordisk genoptager fase 3-udviklingsprogram for liraglutid til behandling af fedme\n",
      "2010-06-22 Novo Nordisk re-initiates phase 3 development of liraglutide for obesity\n",
      "2010-04-27 Interim financial report for the period 1 January 2010 to 31 March 2010\n",
      "2010-04-27 Delårsrapport for perioden 1. januar 2010 til 31. marts 2010\n",
      "2010-03-24 Generalforsamling i Novo Nordisk A/S\n",
      "2010-03-24 Annual General Meeting at Novo Nordisk A/S\n",
      "2010-02-26 Ordinær generalforsamling i Novo Nordisk A/S\n",
      "2010-02-26 Annual General Meeting of Novo Nordisk A/S\n",
      "2010-02-02 Financial statement for 2009\n",
      "2010-02-02 Årsregnskabsmeddelelse for året 2009\n",
      "2010-02-02 Financial statement for 2009\n",
      "2010-01-26 Novo Nordisk receives US approval for Victoza® (liraglutide) for the treatment of type 2 diabetes\n",
      "2010-01-26 Novo Nordisk modtager godkendelse for Victoza® (liraglutid) i USA til behandling af type 2-diabetes\n",
      "2010-01-20 Novo Nordisk får markedsføringstilladelse for Victoza® i Japan\n",
      "2010-01-20 Novo Nordisk receives approval for Victoza® in Japan\n",
      "2009-12-30 Update on timeline for formal feedback on liraglutide from the FDA\n",
      "2009-10-29 Interim financial report for the period 1 January 2009 to 30 September 2009\n",
      "2009-10-29 Delårsrapport for perioden 1. januar 2009 til 30. september 2009\n",
      "2009-09-23 Update on timeline for formal feedback on liraglutide from the FDA\n",
      "2009-08-06 Interim financial report for the period 1 January 2009 to 30 June 2009\n",
      "2009-08-06 Delårsrapport for perioden 1. januar 2009 til 30. juni 2009\n",
      "2009-07-03 Novo Nordisk's  Victoza® (liraglutide) receives marketing authorisation in Europe\n",
      "2009-07-03 Novo Nordisks Victoza® (liraglutid) får markedsføringstilladelse i Europa\n",
      "2009-06-30 Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2009.\n",
      "2009-06-30 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. juni 2009\n",
      "2009-06-28 Novo Nordisk insulin analogues have proven safety profiles\n",
      "2009-06-28 Novo Nordisks insulinanaloger har veldokumenterede sikkerhedsprofiler\n",
      "2009-06-22 Reduction of the share capital and holding of own shares (22 June 2009)\n",
      "2009-04-30 Interim financial report for the period 1 January 2009 to 31 March 2009\n",
      "2009-04-30 Delårsrapport for perioden 1. januar 2009 til 31. marts 2009\n",
      "2009-04-23 Novo Nordisk modtager positiv udtalelse om Victoza® (liraglutide) fra de europæiske registreringsmyndigheder\n",
      "2009-04-23 Novo Nordisk receives positive opinion on Victoza® (liraglutide) from the European regulatory authorities\n",
      "2009-04-02 Update on FDA Advisory Committee meeting on liraglutide for the treatment of type 2 diabetes\n",
      "2009-03-31 Liraglutide briefing documents now available for the FDA Advisory Committee meeting on 2 April\n",
      "2009-03-31 Briefingdokumenterne om liraglutide til mødet i FDA's rådgivende komite den 2. april er nu tilgængelige\n",
      "2009-03-18 Annual General Meeting at Novo Nordisk A/S\n",
      "2009-03-18 Generalforsamling i Novo Nordisk A/S\n",
      "2009-02-24 Annual General Meeting of Novo Nordisk A/S\n",
      "2009-02-24 Ordinær generalforsamling i Novo Nordisk A/S\n",
      "2009-01-29 Financial statement for 2008\n",
      "2009-01-29 Regnskabsmeddelelse for året 2008\n",
      "2008-11-18 FDA reschedules Advisory Committee meeting for liraglutide - no change of review timeline anticipated\n",
      "2008-11-18 FDA meddeler ny dato for møde i rådgivende komite om liraglutide - samlet tidsplan forventes ikke ændret\n",
      "2008-11-07 Major shareholder notification\n",
      "2008-11-07 Storaktionærmeddelelse\n",
      "2008-10-30 Financial statement for the period 1 January 2008 to 30 September 2008\n",
      "2008-10-30 Regnskabsmeddelelse for perioden 1. januar til 30. september 2008\n",
      "2008-09-26 Novo Nordisks kapitalmarkedsdag: opdatering på koncernstrategi\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2008-09-26 Novo Nordisk provides update on corporate strategy at its Capital Markets Day\n",
      "2008-09-09 Major shareholder notification\n",
      "2008-09-09 Storaktionærmeddelelse\n",
      "2008-09-05 FDA schedules Advisory Committee meeting for liraglutide\n",
      "2008-09-05 FDA berammer møde i rådgivende komite om liraglutide\n",
      "2008-09-03 Major shareholder notification\n",
      "2008-09-03 Storaktionærmeddelelse\n",
      "2008-08-07 Financial statement for the period 1 January 2008 to 30 June 2008\n",
      "2008-08-07 Regnskabsmeddelelse for perioden 1. januar til 30. juni 2008\n",
      "2008-07-15 Novo Nordisk files for regulatory approval of liraglutide in Japan\n",
      "2008-07-15 Novo Nordisk indsender registreringsansøgning for liraglutide i Japan\n",
      "2008-06-30 Total number of voting rights and share capital in Novo Nordisk A/S as of 30 June 2008.\n",
      "2008-06-30 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 30. juni 2008\n",
      "2008-06-24 Novo Nordisk receives approval in the US for PrandiMet(TM)\n",
      "2008-06-24 Novo Nordisk opnår godkendelse for PrandiMet® i USA\n",
      "2008-06-16 Significant weight loss sustained in obese people treated with liraglutide for one year\n",
      "2008-06-16 Signifikant vægttab fastholdes hos svært overvægtige efter behandling med liraglutide i et år\n",
      "2008-06-11 Novo Nordisk indstiller klinisk fase 3-forsøg med NovoSeven® til traumebehandling\n",
      "2008-06-11 Novo Nordisk discontinues phase 3 clinical trial with NovoSeven® in trauma\n",
      "2008-06-06 Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide\n",
      "2008-06-06 Klinisk studie viser, at liraglutide giver statistisk signifikant bedre blodsukkerregulering end exenatide\n",
      "2008-05-23 Novo Nordisk indsender registreringsansøgning for liraglutide i USA og Europa\n",
      "2008-05-23 Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe\n",
      "2008-04-30 Financial statement for the period 1 January 2008 to 31 March 2008\n",
      "2008-04-30 Regnskabsmeddelelse for perioden 1. januar til 31. marts 2008\n",
      "2008-04-01 Total number of voting rights and share capital in Novo Nordisk A/S as of 31 March 2008.\n",
      "2008-04-01 Opgørelse af det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 31. marts 2008\n",
      "2008-03-12 Generalforsamling i Novo Nordisk A/S\n",
      "2008-03-12 Annual General Meeting at Novo Nordisk A/S\n",
      "2008-02-20 Annual General Meeting of Novo Nordisk A/S\n",
      "2008-02-20 Ordinær generalforsamling i Novo Nordisk A/S\n",
      "2008-01-31 Regnskabsmeddelelse for året 2007\n",
      "2008-01-31 Financial statement for 2007\n",
      "2008-01-14 Novo Nordisk omprioriterer sine aktiviteter inden for inhalerbar insulin og indstiller udviklingen af AERx®\n",
      "2008-01-14 Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx®\n",
      "2007-12-12 Major shareholder notification\n",
      "2007-12-12 Storaktionærmeddelelse\n",
      "2007-12-11 Afsluttende fase 3-studie bekræfter, at liraglutide har en overbevisende effekt på blodsukkerregulering og vægt\n",
      "2007-12-11 Final phase 3 study confirms very favourable effect of liraglutide on blood glucose control and body weight\n",
      "2007-12-05 Storaktionærmeddelelse\n",
      "2007-12-05 Major shareholder notification\n",
      "2007-11-23 Novo Nordisk stock split information\n",
      "2007-11-23 Information om Novo Nordisks aktiesplit\n",
      "2007-11-20 New phase 2 study shows that liraglutide leads to significant weight loss in obese people\n",
      "2007-11-20 Nyt fase 2-studie viser, at liraglutide medfører signifikant vægttab hos svært overvægtige\n",
      "2007-10-31 Regnskabsmeddelelse for perioden 1. januar til 30. september 2007\n",
      "2007-10-31 Financial statement for the period 1 January 2007 to 30 September 2007\n",
      "2007-10-24 Major shareholder notification\n",
      "2007-10-24 Storaktionærmeddelelse\n",
      "2007-10-09 Major shareholder notification\n",
      "2007-10-09 Storaktionærmeddelelse\n",
      "2007-09-14 Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events\n",
      "2007-09-14 Fase 3-studie bekræfter, at behandling med liraglutide sænker både blodsukker og vægt med lav risiko for hypoglykæmi\n",
      "2007-08-20 Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients\n",
      "2007-08-20 Liraglutide forbedrer blodsukkerregulering og medfører vægttab, viser to fase 3-studier med mere end 2.000 patienter\n",
      "2007-08-03 Financial statement for the period 1 January 2007 to 30 June 2007\n",
      "2007-08-03 Regnskabsmeddelelse for perioden 1. januar til 30. juni 2007\n",
      "2007-06-29 Total number of voting rights and share capital in Novo Nordisk A/S as of 29 June 2007\n",
      "2007-06-29 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 29. juni 2007\n",
      "2007-06-21 Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study\n",
      "2007-06-21 Liraglutide giver en væsentligt bedre blodsukkerregulering end insulin glargine i fase 3-studie\n",
      "2007-06-19 Reduction of the share capital and holding of own shares (19 June 2007)\n",
      "2007-06-01 Total number of voting rights and size of share capital in Novo Nordisk A/S as of 1 June 2007\n",
      "2007-06-01 Det samlede antal stemmerettigheder og den samlede kapital i Novo Nordisk A/S pr. 1. juni 2007\n",
      "2007-05-31 Novo Nordisk's divestment of its ownership of Dako's business activities has now been completed\n",
      "2007-05-31 Salget af Novo Nordisks ejerandel af Dakos forretningsaktiviteter er nu gennemført\n",
      "2007-05-02 Financial statement for the period 1 January 2007 to 31 March 2007\n",
      "2007-05-02 Regnskabsmeddelelse for perioden 1. januar til 31. marts 2007\n",
      "2007-03-07 Annual General Meeting at Novo Nordisk A/S\n",
      "2007-03-07 Generalforsamling i Novo Nordisk A/S\n",
      "2007-02-28 Novo Nordisk sælger sin ejerandel af Dakos forretningsaktiviteter\n",
      "2007-02-28 Novo Nordisk divests its ownership of Dako's business activities\n",
      "2007-02-26 Fase 3-forsøg inden for hjerneblødning viser, at NovoSeven® reducerer blødning, men forbedrer ikke det langsigtede behandlingsresultat\n",
      "2007-02-26 Phase 3 stroke trial shows that NovoSeven® reduces bleeding in the brain, but does not improve long-term clinical outcomes\n",
      "2007-02-20 Ordinær generalforsamling i Novo Nordisk A/S\n",
      "2007-02-20 Annual General Meeting of Novo Nordisk A/S\n",
      "2007-01-31 Financial statement for 2006\n",
      "2007-01-31 Regnskabsmeddelelse for året 2006\n",
      "2007-01-15 Novo Nordisk koncentrerer sine forskningsaktiviteter om terapeutiske proteiner - indstiller forskning i små molekyler\n",
      "2007-01-15 Novo Nordisk focuses research and development on therapeutic proteins - discontinues R&D within small molecules\n",
      "2006-11-30 Novo Nordisk planlægger betydelig udvidelse af sin diabetessalgsorganisation i USA\n",
      "2006-11-30 Novo Nordisk announces major expansion of its diabetes care field force in the US\n",
      "2006-10-27 Regnskabsmeddelelse for perioden 1. januar til 30. september 2006\n",
      "2006-10-27 Financial statement for the period 1 January 2006 to 30 September 2006\n",
      "2006-10-06 Novo Nordisk annoncerer påbegyndelse af tre nye kliniske studier på kapitalmarkedsdag\n",
      "2006-10-06 Novo Nordisk announces initiation of three new clinical studies at Capital Markets Day\n",
      "2006-08-02 Regnskabsmeddelelse for perioden 1. januar til 30. juni 2006\n",
      "2006-08-02 Financial statement for the period 1 January 2006 to 30 June 2006\n",
      "2006-06-23 Reduction of the share capital and holding of own shares (23 June 2006)\n",
      "2006-04-28 Regnskabsmeddelelse for perioden 1. januar til 31. marts 2006\n",
      "2006-04-28 Financial statement for the period 1 January 2006 to 31 March 2006\n",
      "2006-03-31 Ændringer i Novo Nordisks koncerndirektion\n",
      "2006-03-31 Changes in Novo Nordisk's Executive Management\n",
      "2006-03-08 Annual General Meeting at Novo Nordisk A/S\n",
      "2006-03-08 Generalforsamling i Novo Nordisk A/S\n",
      "2006-02-21 Ordinær generalforsamling i Novo Nordisk A/S\n",
      "2006-02-21 Annual General Meeting of Novo Nordisk A/S\n",
      "2006-02-20 Amerikansk undersøgelse vedrørende FN's Olie-for-Mad-program\n",
      "2006-02-20 SEC investigation relating to the United Nations Oil-for Food-Programme\n",
      "2006-01-27 Regnskabsmeddelelse for året 2005\n",
      "2006-01-27 Financial statement for 2005\n",
      "2005-12-20 Novo Nordisk har modtaget begæring om udlevering af dokumenter i USA\n",
      "2005-12-20 Novo Nordisk receives subpoena in the US\n",
      "2005-11-25 Lovende kliniske resultater fra fase 2b-studiet med liraglutide\n",
      "2005-11-25 Promising clinical results from liraglutide phase 2b study\n",
      "2005-10-27 Regnskabsmeddelelse for perioden 1. januar til 30. september 2005\n",
      "2005-10-27 Financial statement for the period 1 January 2005 to 30 September 2005\n",
      "2005-08-11 Regnskabsmeddelelse for perioden 1. januar til 30. juni 2005\n",
      "2005-08-11 Financial statement for the period 1 January 2005 to 30 June 2005\n",
      "2005-06-16 Novo Nordisk opnår FDA-godkendelse af Levemir® og kan dermed som de første tilbyde et fuldt sortiment af insulinanaloger i USA\n",
      "2005-06-16 Novo Nordisk receives US approval of Levemir® and becomes the first company with a full range of insulin analogues in the US\n",
      "2005-04-28 Regnskabsmeddelelse for perioden 1. januar til 31. marts 2005\n",
      "2005-04-28 Financial statement for the period 1 January 2005 to 31 March 2005\n",
      "2005-03-09 Generalforsamling i Novo Nordisk A/S\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2005-03-09 Annual General Meeting at Novo Nordisk A/S\n",
      "2005-02-18 Ordinær generalforsamling i Novo Nordisk A/S - Ændring af bestyrelsens sammensætning\n",
      "2005-02-18 Annual General Meeting of Novo Nordisk A/S - Change of members of the Board of Directors\n",
      "2005-02-16 Opgørelse over besiddelsen af Novo Nordisk-aktier for medlemmerne af bestyrelse og direktion samt for alle insidere og disses nærtstående pr. 11. februar 2005\n",
      "2005-02-16 Holding of Novo Nordisk shares by the members of the Board of Directors, of Executive Management and all insiders and connected persons as per 11 February 2005\n",
      "2005-02-10 Novo Nordisk afhænder aktiepost i Ferrosan A/S\n",
      "2005-02-10 Novo Nordisk divests shareholding in Ferrosan A/S\n",
      "2005-01-28 Regnskabsmeddelelse for året 2004\n",
      "2005-01-28 Financial statement for 2004\n",
      "2005-01-04 Novo Nordisk continues to make progress towards label expansion for NovoSeven® in Europe\n",
      "2005-01-03 Indikationsudvidelsen for NovoSeven® i Europa skrider fortsat fremad\n"
     ]
    }
   ],
   "source": [
    "article_list = []\n",
    "while True:\n",
    "    dummy_url = \"https://www.novonordisk.com/bin/nncorp/news-search?searchtext=null&start=2000-01-01&end=2022-05-24&newspath=/content/dam/nncorp/global/en/investors/content-fragments/ir-materials&limit=10&currentresults=0&function=search&language=all&type=Annual%20reports,Investor%20presentations,5355,5356\"\n",
    "    temp_data = parse_webpage_api(dummy_url)\n",
    "    len_elements = temp_data['data']['numberOfResults']\n",
    "    url = f\"https://www.novonordisk.com/bin/nncorp/news-search?searchtext=null&start=2000-01-01&end=2022-05-24&newspath=/content/dam/nncorp/global/en/investors/content-fragments/ir-materials&limit={len_elements}&currentresults=0&function=search&language=all&type=Annual%20reports,Investor%20presentations,5355,5356\"    \n",
    "    data = parse_webpage_api(url)\n",
    "    elements = data['data']['resultBeanList']\n",
    "    if data != None:\n",
    "        for element in elements:\n",
    "            title = element['title'].strip()\n",
    "            link = f\"https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id={element['id']}\"\n",
    "            date = element['date']\n",
    "            published_date = date.split(\"T\")[0].strip()\n",
    "            article_html = element['newsContent']\n",
    "            site_soup = BeautifulSoup(article_html, \"lxml\")\n",
    "            paragraphs = site_soup.findAll('p')\n",
    "            content = []\n",
    "            for para in paragraphs:\n",
    "                text_p = remove_esc_chars(para.get_text().strip())\n",
    "                content.append(text_p)\n",
    "            text = \" \".join(content)\n",
    "            author = SITE_NAME\n",
    "            thumbnail = \"https://www.novonordisk.com/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico\"\n",
    "            article = (published_date,title,text,link,thumbnail,author)\n",
    "            article_list.append(article)\n",
    "            print(published_date,title)\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "41c49a1b",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:07.466505Z",
     "start_time": "2022-05-24T13:46:07.436581Z"
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>date</th>\n",
       "      <th>title</th>\n",
       "      <th>article</th>\n",
       "      <th>url</th>\n",
       "      <th>thumbnail</th>\n",
       "      <th>author</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2022-05-10</td>\n",
       "      <td>Novo Nordisk and Flagship Pioneering announce ...</td>\n",
       "      <td>Pioneering Medicines and Novo Nordisk Bio Inno...</td>\n",
       "      <td>https://www.novonordisk.com/content/nncorp/glo...</td>\n",
       "      <td>https://www.novonordisk.com/etc.clientlibs/nnc...</td>\n",
       "      <td>Novonordisk</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2022-05-06</td>\n",
       "      <td>Novo Nordisk A/S:</td>\n",
       "      <td>Novo Nordisk – major shareholder announcement ...</td>\n",
       "      <td>https://www.novonordisk.com/content/nncorp/glo...</td>\n",
       "      <td>https://www.novonordisk.com/etc.clientlibs/nnc...</td>\n",
       "      <td>Novonordisk</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2022-05-02</td>\n",
       "      <td>Novo Nordisk – major shareholder announcement</td>\n",
       "      <td>Bagsværd, Denmark, 2 May 2022 – Novo Nordisk t...</td>\n",
       "      <td>https://www.novonordisk.com/content/nncorp/glo...</td>\n",
       "      <td>https://www.novonordisk.com/etc.clientlibs/nnc...</td>\n",
       "      <td>Novonordisk</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2022-04-29</td>\n",
       "      <td>Novo Nordisk A/S – Total number of voting righ...</td>\n",
       "      <td>Bagsværd, Denmark, 29 April 2022 – In accordan...</td>\n",
       "      <td>https://www.novonordisk.com/content/nncorp/glo...</td>\n",
       "      <td>https://www.novonordisk.com/etc.clientlibs/nnc...</td>\n",
       "      <td>Novonordisk</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2022-04-29</td>\n",
       "      <td>Novo Nordisk's sales increased by 24% in Danis...</td>\n",
       "      <td>Financial report for the period 1 January 2022...</td>\n",
       "      <td>https://www.novonordisk.com/content/nncorp/glo...</td>\n",
       "      <td>https://www.novonordisk.com/etc.clientlibs/nnc...</td>\n",
       "      <td>Novonordisk</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         date                                              title  \\\n",
       "0  2022-05-10  Novo Nordisk and Flagship Pioneering announce ...   \n",
       "1  2022-05-06                                  Novo Nordisk A/S:   \n",
       "2  2022-05-02      Novo Nordisk – major shareholder announcement   \n",
       "3  2022-04-29  Novo Nordisk A/S – Total number of voting righ...   \n",
       "4  2022-04-29  Novo Nordisk's sales increased by 24% in Danis...   \n",
       "\n",
       "                                             article  \\\n",
       "0  Pioneering Medicines and Novo Nordisk Bio Inno...   \n",
       "1  Novo Nordisk – major shareholder announcement ...   \n",
       "2  Bagsværd, Denmark, 2 May 2022 – Novo Nordisk t...   \n",
       "3  Bagsværd, Denmark, 29 April 2022 – In accordan...   \n",
       "4  Financial report for the period 1 January 2022...   \n",
       "\n",
       "                                                 url  \\\n",
       "0  https://www.novonordisk.com/content/nncorp/glo...   \n",
       "1  https://www.novonordisk.com/content/nncorp/glo...   \n",
       "2  https://www.novonordisk.com/content/nncorp/glo...   \n",
       "3  https://www.novonordisk.com/content/nncorp/glo...   \n",
       "4  https://www.novonordisk.com/content/nncorp/glo...   \n",
       "\n",
       "                                           thumbnail       author  \n",
       "0  https://www.novonordisk.com/etc.clientlibs/nnc...  Novonordisk  \n",
       "1  https://www.novonordisk.com/etc.clientlibs/nnc...  Novonordisk  \n",
       "2  https://www.novonordisk.com/etc.clientlibs/nnc...  Novonordisk  \n",
       "3  https://www.novonordisk.com/etc.clientlibs/nnc...  Novonordisk  \n",
       "4  https://www.novonordisk.com/etc.clientlibs/nnc...  Novonordisk  "
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "temp_df = pd.DataFrame(article_list,columns=['date','title','article','url','thumbnail','author'])\n",
    "temp_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "7f309266",
   "metadata": {
    "ExecuteTime": {
     "end_time": "2022-05-24T13:46:07.672111Z",
     "start_time": "2022-05-24T13:46:07.468495Z"
    }
   },
   "outputs": [],
   "source": [
    "#to csv\n",
    "temp_df.to_csv('novonordisk news.csv')\n",
    "\n",
    "#to json\n",
    "temp_df.to_json('novonordisk news.json')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  },
  "toc": {
   "base_numbering": 1,
   "nav_menu": {},
   "number_sections": true,
   "sideBar": true,
   "skip_h1_title": false,
   "title_cell": "Table of Contents",
   "title_sidebar": "Contents",
   "toc_cell": false,
   "toc_position": {},
   "toc_section_display": true,
   "toc_window_display": false
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
